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CBA Controlled before-after  
CBNCP Community based newborn care package 
CI Confidence Interval 
COPD Chronic obstructive pulmonary disease 
COVID-19 Coronavirus disease 2019 
DALYs Disability-adjusted life years 
DiD Difference-in-differences 
DRKS German national trial registry (Deutsches Register Klinischer Studien) 
EBPH Evidence-based public health 
EPOC Effective Practice and Organisation of Care 
EU European Union 
FCTC Framework Convention on Tobacco Control  
FERITS Framework for Enhanced Reporting of Interrupted Time Series  
ITS Interrupted time series 
LMICs Low- and middle income countries 
NRCTs Nonrandomised, controlled trials 
OR Odds ratio 
PM Particulate matter 
RCT Randomised Controlled Trial 
ROBINS-I Cochrane risk of bias tool to assess non-randomized studies of interventions 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus type 2  
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public health i.e. the health of entire populations is officially recognized as a key driver for 
the wellbeing of society [4]. Health indirectly influences most areas of human life and hence 
should be considered in policies across all sectors, budgets and government priorities [5]. Today, 
as emphasised during the on-going global SARS-CoV-2/COVID-19 pandemic, public health plays 
a vital role in society addressing complex political, social, economic and environmental problems 
through approaches that affect multiple sectors [5]. A problem of major public health signifi-
cance in industrialised and developing countries alike is, for example, the increase in chronic 
diseases, such as diabetes, hypertension, or chronic obstructive pulmonary disease [5, 6]. Ad-
dressing risk factors for chronic diseases thus plays a major role in prevention efforts as detailed 
in Box 1.
Box 1.Tobacco smoke as a major risk factor worldwide
Tobacco smoke represents a critical risk factor for public health. Smoking and the 
exposure to secondhand smoke are responsible for over eight million deaths world-
wide every year according to the World Health Organisation (WHO) [7]. In 2015, to-
bacco smoke caused a disease burden of 150 million disability-adjusted life years 
(DALYs), mainly for cancers, chronic obstructive pulmonary disease (COPD), and 
other chronic respiratory disease. It was ranked among the top five risk factors for 
109 countries and its disease burden is still growing [8]. Interventions targeting this 
risk factor thus play a major role in public health. To reduce human consumption and 
exposure to tobacco smoke and thereby limit its impact on mortality and chronic 
disease prevalence, governments have implemented different interventions. With 
the adoption of the WHO Framework Convention on Tobacco Control (FCTC) in 2003, 
all WHO member states are obliged to implement interventions on a range of differ-
ent policy areas, such as the monitoring of tobacco use and prevention policies, the 
protection of the population from tobacco use, taxes on tobacco products, and much 
more [9].
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A typical public health question may ask, for example, how to best address a particular risk factor 
and thus reduce the associated disease burden at the population-level. This is often addressed 
through behavioural or environmental interventions, i.e. interventions that aim to modify the 
behaviour of a population (e.g. through health promotion or prevention programmes, such as a 
smoking cessation programme) or the environment in which a population lives (e.g. through 
creating smoke-free environments, such as smoke-free work places). Such public health inter-
ventions, including also interventions in the field of health systems, health services, and health 
policy, are often quite complex [10-13]. This complexity, embodied for example in multiple, long 
and complex causal pathways, contribute to making an evaluation difficult. The effectiveness of 
an intervention may vary according to user compliance, the delivery of the intervention, health 
system characteristics, programming and other policy measures, which are part of the wider 
geographical, socio-economic, political and cultural context [14, 15]. These aspects, among oth-
ers, make evaluating the effectiveness of public health interventions challenging. Box 2. illus-
trates potential challenges by providing an example of an environmental public health interven-
tion, the introduction of a smoking ban. 
Box 2. Smoking bans in public places as a means to reduce exposure to tobacco 
smoke
The introduction of a smoking ban to reduce chronic respiratory diseases represents 
a public health intervention designed to change the physical and social environment 
in which people live. There may be, however, many different factors that can influence 
both the effectiveness of the smoking ban, as well as chronic respiratory disease out-
comes.
Examples include:
Acceptability, compliance and enforcement of the smoking ban 
Other interventions targeting tobacco smoke: e.g. tax increases or the intro-
duction of packaging images
Other public health measures: e.g. low emission zones to reduce ambient air 
pollution that may have an influence on chronic respiratory disease outcomes
Changes to the healthcare system: e.g. improvements in healthcare, such as 
disease management programmes that may influence disease outcomes




Policy makers are thus confronted with not only pressing but also complex public health prob-
lems and need to make challenging decisions that affect whole populations and require limited 
resources that may miss on other ends. Therefore, these decisions should be based on the best 
evidence available. Rigorous primary studies as well as systematic reviews represent an essential 
basis for policymaking and are the cornerstone of evidence-based public health (EBPH) [15, 16]. 
Systematic reviews identify and appraise all available evidence of relevance to a specific ques-
tion. Systematic reviews are characterised by their standardized and reproducible way of search-
ing, screening and selecting the studies, including a statistical, graphical or narrative synthesis 
of the findings to provide an overall effect of the interventions assessed [17]. They can be quan-
titative assessments of effectiveness and/or cost-effectiveness but can also be qualitative focus-
ing on other important factors such as acceptability or feasibility of an intervention [18]. 
Cochrane, an international network of researchers and health professionals has focused on con-
ducting high-quality systematic reviews mostly of effectiveness to inform health decisions. 
Cochrane reviews provide the highest standard of systematic reviews [17]. The answers that 
systematic reviews can provide, however, are only as good as the evidence from the studies they 
include [19]. Rigorous studies are therefore an essential basis to provide reliable answers to 




In part because of the above-mentioned evaluation difficulties with regards to the complexity 
of many public health questions, different types of studies may need to be put into practice. In 
clinical settings, randomised controlled trials (RCTs) are considered the gold standard to assess 
intervention effectiveness because of their ability to account for observable as well as unobserv-
able differences between study groups [20]. RCTs or cluster RCTs are, however, under certain 
circumstances not always practically, ethically or financially feasible or applicable particularly to 
assess environmental public health interventions that are implemented on a large-scale popu-
lation level [15, 21-24]. It would, for example, be very difficult and potentially unethical to ran-
domly select different cities or regions to assess the effectiveness of a smoking ban. Further-
more, in many cases the intervention has already been implemented as the result of a political 
decision and a retrospective evaluation is necessary.  
 
Under such circumstances, nonrandomised study designs may thus be the only means to assess 
the effectiveness of public health interventions in real life [25-27]. In nonrandomised studies, 
the selection of the study participants is based on approaches other than randomisation, for 




This implies that the study is more prone, for example, to selection bias and confounding, and 
that it is more difficult to link the effect causally to the intervention. The risk of drawing mis-
leading conclusions is therefore higher than in RCTs, yet they are easier to implement in real 
world settings [22, 25, 26, 29, 30]. Nonrandomised studies include a large variety of different 
study designs, such as cohort studies, case-control studies, controlled before-after (CBA) stud-
ies, interrupted time series (ITS) studies and nonrandomised, controlled trials (NRCTs) [26].  
 
Increasing with the need of policymakers to decide on complex public health matters, nonran-
domised studies have been more frequently conducted as well as included in systematic reviews 
of interventions [25, 31]. Alongside, primary researchers as well as systematic reviewers have 
been presented with methodological challenges [25, 27, 32, 33]. Many studies reveal methodo-
logical problems and are often poorly described, which complicates the searching for and 
screening of the studies for review authors [25, 32, 34, 35]. Additional concerns have been raised 
regarding how to appraise and synthesize the results derived from nonrandomised studies [36], 




Before introducing specific study designs, it is worthwhile to clarify the wide range of terminol-
ogy used to describe nonrandomised studies in general. Nonrandomised studies, for example, 
are often referred to as observational studies. However, some, including Cochrane, discourage 
the use of this term for studies assessing intervention effects as it is most commonly used in 
researching risk factors and exposures [26]. Specifically in the context of intervention research, 
researchers have distinguished between experimental (i.e. RCTs) and quasi-experimental stud-
ies. Quasi-experimental studies are 
they aim to make assumptions about causal inferences. Quasi-experimental studies do so, how-
ever using non-random methods for assignment into intervention and control group [20]. Fur-
es 
that investigate interventions that occurred naturally and are not under the control of the re-
searcher. These include mostly (large-scale) policy and programme evaluations [29]. Many 
quasi-experimental studies are therefore also natural experiments. 
 
Different from cohort studies or case-control studies, which can provide useful evidence about 




ating intervention effects [20, 37]. Indeed, ITS and CBA studies are the most often included non-
randomised study designs in Cochrane reviews [25, 38], yet within public health research they 
are not yet fully implemented and understood [25, 26, 38, 39].  
2.3.1. The interrupted time series study  
The ITS study is considered among the strongest quasi-experimental designs due to its powerful 
and flexible method for dealing with trend data [40, 41]. It uses data collected at multiple time 
points over a longer period of time before and after an intervention (
ure an intervention effect against a pre-intervention trend [42]. It thereby predicts the differ-
ence between what would have happened in absence of the intervention (the counterfactual) 
and the actual data observed (see Figure 1). The study design lends itself to retrospective eval-
uations using routine data [29, 42] and of interventions and outcomes measured at population 
level [37, 43]. The ITS study is particularly suitable for the evaluation of natural experiments, 
that is of naturally occurring events or interventions that were implemented without direct re-
searcher involvement [29]. The intervention effect can be measured as a change in level of the 
outcome, i.e. an immediate drop or increase of the outcome, as well as a change in slope, i.e. a 
change in the outcome trend over the post-intervention time period [35].  
 
The ITS study design allows, through appropriate statistical analysis, to control for secular 
trends, thereby accounting for a natural increase or decrease of the outcome over time that 
could have otherwise been wrongly attributed to the intervention effect. It also allows for the 
investigation of seasonal or other regular effects, random fluctuations of the outcome, autocor-
relation of the data points, and duration of the intervention effect [35]. As the intervention ef-
fect is usually measured within the same population, selection bias and confounding due to 
group differences do not pose a problem [37]. 
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Figure 1. Illustration of the interrupted time series study design (adapted from Grimshaw et al. 
[44])
While public health research has recognized the value of applying ITS studies [23, 25, 46], there 
is still some discussion going on as to what constitutes an ITS study [47]. Recent studies have 
focused on clarifying the methodological concepts of the ITS study design [23, 37, 43, 46, 48, 
Box 3. Example of an ITS study: evaluation of flavoured cigar regulations with 
wholesale tobacco volumes in Canada 
The aim of the study was to investigate the impact of a Canadian policy implemented 
in 2009 that prohibited flavours (except the flavour menthol) in small cigars on sales 
of these products. Using an interrupted time series design, the study authors analysed 
wholesale unit data from early-2001 until the end of 2016, which are reported quar-
terly to the Canadian government. The analyses were adjusted for seasonal trend and 
both sales of tobacco products with and without flavour were analysed. The regula-
tions w
flavoured cigars. The study shows that the Canadian public health policy restricting 
flavours in tobacco products had a substantial impact on cigar sales. The impact of a 
flavour ban could be increased by a comprehensive policy including all flavours and 
all product types without exemptions. 




49], looking more closely at the analysis approaches [23, 35] and comparing the effect estimates 
to those of cluster RCTs [50-52].  
Ramsay et al found that most ITS studies were inappropriately analysed, neglecting co-interven-
tion effects and leading in many cases to a statistical overestimation of the effect estimates. 
Another study found that many ITS studies include an insufficient number of pre-intervention 
time points, which leads to difficulties in estimating an underlying secular trend and thus to 
wrong conclusions of significant effects [53]. The Cochrane Effective Practice and Organisation 
of Care (EPOC), a Cochrane group, which focuses on assessing health care interventions on a 
population level, has included CBA and ITS studies in their reviews. In the absence of any formal 
guidance they developed pragmatic methodological criteria for review authors in order to es-
tablish a minimum threshold of study quality included in the systematic reviews. For ITS studies, 
these include a clearly defined intervention time point and a minimum of three time points each 
before and after the intervention.  
 
2.3.2. The controlled before-after study 
CBA studies evaluate an intervention effect by investigating observations, which are made be-
fore and after implementation of an intervention, in a group that receives the intervention and 
in a control group that does not. In CBA studies, clusters such as healthcare centres or hospitals 
are allocated to an intervention or control group. The analysis compares change scores in the 
intervention and control group, assuming parallel trends between the groups [54, 55]. The con-
trol group should therefore be similar in terms of baseline characteristics and performance to 
the intervention group, assuming the intervention effect to be caused by the intervention im-
plemented in the intervention group [53, 54].   
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Figure 2. Illustration of the controlled before-after study design (adapted from Grimshaw et al. 
[44])
Box 4. Example of a CBA study: Evaluation of an educational intervention for 
smoke-free adolescents
The aim of the study was to assess the association between an educational inter-
vention to prevent the onset of smoking among adolescents and the smoking prev-
alence in two high schools in La Plata, Argentina, implementing a controlled before-
after study design. Adolescents between 12 and 13 years in one of the high schools 
received the educational intervention. An assessment of smoking prevalence was 
conducted in both high schools in 2010 immediately prior to the educational inter-
vention and in 2011 and 2012, for follow-up.  Multiple regression models were con-
ducted to analyse the association between the intervention and smoking preva-
lence, adjusting for determinants that were associated with adolescent smoking 
(smoking family members, sex). The adjusted odds ratio (OR) for smoking at the 
high school where adolescents received the intervention as compared to the school 
that did not receive the educational intervention was 0.54 (95% confidence interval 
(CI) 0.35-0.83) in 2011 and 0.98 (95%CI 0.60-1.61) in 2012. The educational inter-
vention had a positive short-term impact, which was, however, not maintained 
over time.





The methodological literature on CBA studies is, however, limited. Few studies have looked at 
CBA studies among other nonrandomised studies and disagree on methodological characteris-
tics, such as investigator control over the intervention allocation and other features that may 
separate the CBA study design from other designs, such as the nonrandomised controlled trial 
[22, 24, 39, 54]. Cochrane EPOC defines minimum methodological criteria, such as at least two 
sites per intervention and control group and contemporaneous data collection in both groups 
(EPOC). Eccles et al. [53] and Grimshaw et al. [54] emphasize the need for an appropriate control 
group and appropriate statistical analysis. The challenge for CBA studies is the selection of an 
appropriate control group and there are several methods, such as propensity score matching, 
to attempt to have equal baseline measures. However, even in CBA studies with apparently well-
matched control groups performance at baseline may differ. In many cases this has led to inap-




Overall, there is no coherent picture as to how CBA and ITS studies should be designed, con-
ducted and analysed in the most appropriate way. Linked to this problem, systematic reviewers 
have difficulties to search for and include CBA and ITS studies, while at the same time their 
higher internal validity compared to other nonrandomised study designs triggers discussions 
about how to reflect this in systematic review synthesis and quality assessment [12]. This situa-
tion is thus challenging both for primary researchers evaluating the effectiveness of public 
health evaluations, as well as for those synthesizing these studies at the systematic review level. 
 
Researchers would benefit from a clearer picture of CBA and ITS studies considering study de-
sign, data collection and analysis in order to properly conduct these studies. Likewise, this clarity 
would make it easier for systematic reviewers to search for, include and synthesize CBA and ITS 
study designs in systematic reviews [57]. Ultimately, decision makers would have more certainty 
in terms of recommending for or against an intervention, if the studies included in a systematic 







The objectives of this doctoral thesis were therefore to  
 
i. investigate how CBA and ITS study designs have been conducted at the primary study 
level and have been utilized at the systematic review level 
 
ii. contribute to improving the use and conduct of CBA and ITS studies through the con-
duct of good-practice primary studies and a methodological investigation of study de-
sign and analysis characteristics 
 
2.6.  
This PhD thesis comprises two first author publications that were published in highly ranked 
international journals.
 
I. Polus S, Pieper D, Burns J, Fretheim A, Ramsay C, Higgins JPT, et al.,  Heterogeneity in 
application, design, and analysis characteristics was found for controlled before-after 
and interrupted time series studies included in Cochrane reviews. J Clin Epidemiol, 
2017. 91: p. 56-69. 
 
II. Polus S, Burns J, Hoffmann S, Mathes T, Mansmann U, Been JV, et al. Interrupted time 
series study found mixed effects of the impact of the Bavarian smoke-free legislation 
on pregnancy outcomes. Sci Rep, 2021. 11(1): p. 4209. 
 
It further comprises an additional publication, to be submitted shortly, which is not a formal part 
of this doctoral thesis but was conducted within the context of the doctoral research. 
 
III. Polus S, Burns J, Pedron S, Paudel D, and Rehfuess E, The choice of analysis in 










Given the above outlined challenges related to CBA and ITS studies, the first project of this thesis 
set out to examine detailed characteristics of CBA and ITS studies. The resulting first publication 
investigated the use (application characteristics) and the conduct (design and analysis charac-
teristics) of the studies on two levels, the primary research level as well as the systematic review 
level. Specifically, the study examined for what type of interventions the studies were applied, 
the study design characteristics themselves and how the analyses were undertaken in the stud-
ies. It further looked at the characteristics of the Cochrane reviews that included the CBA and 
ITS studies and how the review authors as well as the primary researchers defined and labelled 
the studies. This was done to receive an updated and more detailed picture of the systematic 
reviews that included nonrandomised studies, following previous study findings of characteris-
tics of systematic reviews including nonrandomised study designs by Ijaz et al. [38].  
2.7.2. Methods 
For this purpose, a group of experts with methodological expertise in these study designs as well 
as systematic reviewers were gathered. The study included a two-step process with selection 
and data extraction at two levels, the systematic review level as well as primary study level. In a 
first step, Cochrane systematic reviews published between June 2012 and March 2015 that in-
cluded nonrandomised study design were selected. For these systematic reviews detailed char-
acteristics, such as which types of study designs they included, were examined. In a second step, 
the systematic reviews were categorized according to ten pre-specified intervention types. Two 
reviews per intervention type were selected that included at least two studies using the respec-
tive study designs. In this way, an assessment of a heterogeneous sample of studies applied in 
different fields of health research was ensured. The PhD candidate together with one of the co-
authors then independently extracted detailed information on the publication (i.e. general as-
pects, such as publication year), application (e.g. type and level of intervention), and methodo-
logical (including information about study design, data collection and data analysis) characteris-
tics, and reported strengths and weaknesses of the study designs. The experienced group of co-
authors ensured a detailed and thorough examination of the included studies, which required 
in many cases extensive scientific discussion.  
2.7.3. Results  
Out of 136 reviews that considered nonrandomised studies and included 1956 primary studies, 




into intervention type assessed, 21 CBA and 18 ITS studies were selected for primary study anal-
ysis. Due to the abundance of information gathered on the characteristics of the systematic re-
views as well as primary studies, the final publication includes only the most relevant study find-
ings while the data extraction was much more elaborate. The Cochrane reviews revealed great 
differences with regards to definitions and criteria of CBA and ITS studies. While most reviews 
reported to have used the EPOC criteria as a selection criterion, it seemed difficult for many 
review authors to then correctly apply the criteria to the primary study under consideration. 
Some included primary studies did not comply with the EPOC criteria or even more basic char-
 study. On a primary study level the findings showed 
a discrepancy between study design and the actual statistical analysis, showing that researchers 
often did not use the collected data in the statistical analysis. However, poor reporting of the 
primary studies often prevented identification of the analysis methods. 
2.7.4. Discussion  
A detailed discussion of key characteristics of both study designs and considered related chal-
lenges aims to distil key aspects towards accepted definitions and features of CBA and ITS stud-
ies. For example, for CBA studies the advantage of including at least two intervention and two 
appropriate control sites is pointed out. Further, the potential problem of defining what consti-
tutes the site in case of higher-level clustering is discussed. For ITS studies, for example, the 
discussion explicitly mentions the importance of the statistical analysis, which should include 
multiple measurements over time, adjusting for important secular trends. The study findings 
resulted in and contributed to several further projects that were conducted in the context of 
this PhD thesis and are therefore discussed below.  
2.7.5. Dissemination and further use of study findings 
The insights of the first project were disseminated in subsequent years at workshops and 
presentations in Germany and abroad for primary study researchers and systematic reviewers 
to increase their understanding and thus conduct of the study designs and their correct use in 
systematic reviews. In these workshops the study designs were explained in detail and infor-
mation given on what to consider when (a) conducting them and (b) including them in system-
atic reviews. A list of presentations and workshops is listed under the publication list of this 
doctoral thesis. 
 
The insights also informed the new version of the Cochrane Handbook, which advises reviewers 
on how to include studies not by study label but distinct features [26].  The concentration on 
study features instead of study labels is also reflected in the recent Cochrane risk of bias tool to 




specific versions for CBA and ITS study designs, distinguishing more broadly between uncon-
trolled studies (simple before-after studies, ITS studies) and controlled studies (e.g. controlled 
ITS, CBA studies) assessing risk of bias according to different study design features [59]. 
 
Insights of publication I informed the parallel work on two Cochrane reviews, assessing the ef-
fects of complex public health interventions, in which the PhD candidate was a co-author. Burns 
et al. [60] assessed the effects of air pollution interventions on air quality and health outcomes 
and von Philipsborn et al. [61] investigated environmental interventions to reduce the consump-
tion of sugar-sweetened beverages. Both included CBA and ITS studies and insights from our 
methodological work fed into the methodological approach implemented in these systematic 
reviews. This will be briefly described using the systematic review by Burns et al. [60].  
 
Ambient air pollution, caused by particulate matter (PM) of various sizes that mix in the atmos-
phere [62], is an important public health risk factor, contributing to a high mortality and mor-
bidity, especially in low- and middle-income countries (LMICs) [63, 64]. The systematic review 
objective was to assess the effectiveness of interventions to reduce ambient PM air pollution in 
reducing pollutant concentrations and improving associated health outcomes. The findings of 
our methodological study led to a much more careful identification, selection and in-depth char-
acterisation of ITS and CBA studies, which was not based on study labels but detailed study fea-
tures. Particularly problems associated with the conduct and analysis of ITS and CBA studies 
were confirmed in the review. We were not able to include many ITS studies as such in the re-
view as they were inadequately analysed; more specifically, these studies assessed detailed se-
rial data, yet analysed them in a way that did not make use of this data. Similarly, the analyses 
of several included CBA studies were conducted in such a way that the quantitative data on 








In a second project, the lessons learned were applied in a rigorously conducted ITS study evalu-
ating a complex public health intervention, the introduction of the smoke-free legislation in Ba-
varia. Recent research has focused on the impact of smoking and the exposure to secondhand 
smoke on pregnancy outcomes. Specifically, the exposure of tobacco smoke during pregnancy 
seems to affect the unborn baby and can result in decreased birth weight, preterm birth, and 
other complications, which may have life-long consequences [65]. Previous evidence suggests 
that smoke-free legislation, prohibiting smoking e.g. in public places, such as bars and restau-
rants, public buildings and institutions does not only improve adult health, but may also improve 
the health of newborn babies [66, 67]. Our study objective was therefore to assess the impact 
of the smoke-free legislation on several pregnancy outcomes.  
2.8.2. Methods 
As a well-designed and carefully prepared ITS study can increase the confidence with which the 
effect estimate can be attributed to the intervention [53], additional efforts and time went into 
the preparation of a detailed study protocol. In order to elaborate the complexity of the inter-
vention, it included a system-based logic model outlining the long causal pathway between the 
smoke-free legislation and the pregnancy outcomes. The logic model further detailed potentially 
important co-interventions, i.e. simultaneous interventions or natural events that can influence 
the outcome and thus present the biggest threat to internal validity of an ITS study [35, 37]. 
After several iterations of the protocol, it was registered with the German national trial registry 
DRKS (study ID: DRKS00014805). In Bavaria, the implementation process of the smoke-free leg-
islation took over two years, as it was first implemented in 2008 but loosened again in 2009 due 
to political reasons. The final implementation of the smoke-free legislation was in 2010. For our 
main impact model, we hypothesized a level as well as a slope change in preterm birth, small for 
gestational age (primary outcomes), low birth weight, stillbirth, and very preterm birth (second-
ary outcomes) in 2010. The structure of the data demanded the need for an advanced statistical 
analysis that accounted for seasonal patterns and remaining autocorrelation structures in a Pois-
son or more flexible negative binomial distribution. We investigated the effects of co-interven-
tions through sensitivity analyses or ruled them out through choosing an impact model with a 
shorter time period. Due to uncertainties in the timing of the implementation process of the 
smoke-free legislation as well as in the occurrence of measurable effects on pregnancy out-
-year transition period 
from 2008 until 2010 in further sensitivity analyses. As population health interventions are es-




free legislation according to socio-economic status and maternal smoking status in subgroup 
analyses. 
2.8.3. Results 
The study found heterogeneous results regarding the impact of the smoke-free legislation. Most 
outcomes show statistically non-significant, small effects in both directions. For example, for 
preterm birth, we observed a rate ratio of 1.0163 (95%CI 0.9762, 1.0580) for the level change 
and a rate ratio of 0.9995 (95%CI 0.9976, 1.0013) for the slope change. We found slightly greater 
and statistically significant effects for both level and slope changes of the secondary outcome 
very preterm birth: a rate ratio of 0.8960 (95%CI 0.8413, 0.9542) for the level change and a rate 
ratio of 0.9954 (95% 0.9928, 0.9982) for the slope change. The majority of sensitivity analyses 
confirm these results, i.e. small and statistically non-significant effects for level and slope change 
for most outcomes except very preterm birth where the effects are of a similar magnitude alt-
hough not statistically significant. Also the subgroup analyses on maternal smoking status and 
socio-economic status do not show clear effects.  
2.8.4. Discussion 
The study uses rigorous methods and was carefully prepared to assess the association between 
the smoke-free legislation and pregnancy outcomes in Bavaria. We suggest several aspects with 
regards to the complexity of the intervention and the context, in which it was implemented, as 
well as design-inherent methodological features that may explain why our study did not show a 
clear impact of the legislation. Particularly the methodological discussion may be important for 
further research in this field. For example, w -
regarding how to analyse ITS studies. Among the most popular methods are segmented regres-
sion analysis and Auto Regressive Integrated Moving Average (ARIMA) [68]. However, when go-
ing into detail, small decisions on which parameters to include in a statistical model may have 
important implications for the effect estimates [69]. Profound statistical knowledge is a require-
ment for conducting ITS studies, especially in cases where the data are characterised by non-
linear trends. Furthermore, some statistical challenges of ITS studies have not yet been investi-
gated in-depth and detailed statistical guidance for analysing ITS studies is still missing. This may 
include, for example, aspects, such as the inherent heterogeneity of population characteristics 
when data are aggregated, e.g. from different healthcare facilities. Ewusie [70] has worked on a 
weighted segmented regression method that can be more precise and less biased, however, 
further research needs to investigate remaining challenges regarding how to best analyse such 




2.8.5. Further applications of quasi-experimental study designs within the context 
of this doctoral research 
Polus et al. [3] (see additional publication III) applies the set of common analysis methods for 
CBA studies encountered in publication I. and explores their implications for study findings. 
Many CBA studies do apply a correct design, i.e. they collect the data in control and intervention 
sites or groups before and after the intervention. In the statistical analysis, however, they do 
not fully exploit the potential of their collected data in the statistical analysis. This study there-
fore compared different commonly applied analysis methods to illustrate the consequences of 
the choice of analysis in terms of effect size and precision of the study findings using a previously 
conducted CBA study on a community-based newborn health programme in Nepal [71]. In Ne-
pal, neonatal mortality still poses a substantial public health problem with 21 deaths per 1000 
live births in 2016 [72]. Simple interventions including, for example, antenatal care visits and 
home-based treatment can substantially reduce the risk of neonatal mortality. The Nepalese 
government therefore introduced a community-based newborn care package (CBNCP), compris-
ing several community-based and home-based interventions aiming to reduce neonatal mortal-
ity. Paudel et al. [71] investigated the effects of the CBNCP in Nepal comparing ten intervention 
districts, where the programme had been implemented, with ten control districts where the 
intervention had not been introduced.  
The study results of additional contribution III reveal differences in effect size and associated 
statistical precision related to the effectiveness of the CBNCP in Nepal according to statistical 
analysis choice. 
as well as systematic reviewers. Primary researchers should carefully choose their analysis 
method and fully exploit the strengths of the CBA study design. Systematic reviewers should, 
where needed, re-analyse the data before including findings of a CBA study in the evidence syn-
thesis.  
 
The work by Burns et al. [73] represents a further application of quasi-experimental study de-
signs in primary research. The study, in which the PhD candidate was a co-author, assessed the 
impact of the COVID-19 mitigation measures in March 2020 on air quality in Munich, Germany, 
through a controlled ITS study as well as a synthetic control design. The study hypothesized that 
the mitigation measures implemented due to the emergent SARS-CoV-2/COVID-19 pandemic 
caused an immediate reduction of traffic leading to a reduction of NO2 concentrations. The syn-
thetic control design was used as a complementary approach to the controlled ITS study ap-
proach. Both approaches compared changes in NO2 in 2020 to changes occurring in 2014-2019. 
The c-ITS as well as the SC approach support the hypothesis of an immediate improvement of 
air quality at traffic sites. This natural experiment suggests that traffic reducing policies for highly 






The first publication of this doctoral thesis, the methodological review of CBA and ITS study 
characteristics published in 2017, was one of the first studies that undertook a detailed exami-
nation of CBA and ITS study design characteristics and of the characteristics of the systematic 
reviews that made use of these study designs. Since then, other methodological studies have 
confirmed our findings and have contributed to providing guidance, notably regarding the ITS 
study design [23, 37, 48, 49, 68, 74]. Hudson et al. [68] follow up on our work as well as on that 
of Ramsay et al. [35] and Jandoc et al. [75], including a wide range of systematic reviews pub-
lished in 2015 and assessing detailed design and analysis characteristics of 116 ITS studies that 
were included in these reviews. Turner et al. [74] also investigated 200 ITS studies published 
between 2013 and 2017 that evaluated public health interventions or exposures. They particu-
larly highlight the need for formal reporting guidelines to increase quality of reporting of design 
and analysis features and results of ITS studies [68, 74]. Indeed, reporting guidelines for ITS stud-
ies are currently under development (see Framework for Enhanced Reporting of Interrupted 
Time Series (FERITS), registered in 2018) [76]. Turner et al. [74] highlight the need for an im-
proved description of the statistical methods and approaches to adjust for and estimate auto-
correlation. Hudson et al. [68] investigated that only 6% of their included ITS studies referred to 
a study protocol while Lopez Bernal et al. [37] emphasize the importance of pre-specifying the 
methods and especially the impact model to reduce the risk of detecting an effect due to chance 
when purely relying on the outcome data.  Lopez Bernal et al. [37], Lopez Bernal et al. [49] con-
tributed much in providing detailed step-by-step guidance on how best to plan and conduct an 
ITS study including elaborate considerations on the choice of modelling the effect and the im-
pact model. Publication II. of the doctoral thesis, the ITS study on the Bavarian smoke-free leg-
islation, may serve as a role model regarding the reporting and execution of methods. The study 
was registered based on a detailed study protocol, which pre-specified the impact model, the 
main statistical analysis including sensitivity and subgroup analyses, and a detailed logic model 
displaying the complexity of the intervention and how this informed the study methods. The 
publication also provides the statistical code for researchers to be able to follow and, as appro-
priate, replicate our methodological approach.  
 
The methodological literature on CBA studies, on the other hand, is still limited. Publication I, 
which analyses the methodological characteristics of CBA and ITS studies and additional contri-
bution III thus contribute much by providing some guidance to researchers on how to conduct 
CBA studies and appraise them at the systematic review level. However, there has been much 
progress in utilizing and describing other quasi-experimental study designs that can equally pro-
vide useful evidence for complex public health interventions. These include both the controlled 




designs [55]. The scientific discourse has now advanced from that of the beginning of this doc-
toral research, currently discussing for example the commonalities and differences between the 
DiD design, the synthetic control and the controlled ITS study design and their terminology [77, 
78]. Lopez Bernal et al. [48] explain in detail the controlled ITS study, including potential control 
types as well as statistical analysis approaches. Particularly the proposed methodological exten-
sions such as the inclusion of a synthetic control have caused confusion as to how this is different 
from a DiD design. Lopez Bernal et al. [77] argue that the DiD design typically refers to a CBA 
-intervention) time point and a 
single post-intervention time point, or where pre- and post-intervention means are compared 
[21, 79, 80]. Thus, a key difference between 
the DiD and controlled ITS study design is the adjustment for secular trend. The synthetic control 
design can be used as a complementary approach to the controlled ITS study see, for example, 
Burns et al. [73], not necessarily only as an alternative [77]. Clearly, the methodological devel-
opment of quasi-experimental studies to evaluate population level public health interventions 
continues to be active [73, 81, 82].  
 
This doctoral thesis has thus contributed to the methodological discussion and refinement of 
CBA and ITS studies. It provides a baseline for the ongoing research of developing, defining, and 
clarifying quasi-experimental methods for the evaluation of complex public health interventions. 
With further advancement and clarification of the methods used in and critically needed for 
public health research, policy-makers will increasingly have the opportunity to make clear, evi-
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Abstract
Objectives: The aim of the study was to examine the application, design, and analysis characteristics of controlled before-after (CBA)
and interrupted time series (ITS) studies and their use in Cochrane reviews.
Study Design and Setting: We searched the Cochrane library for reviews including these study designs from May 2012 to March 2015
and purposively selected, where available, two reviews each across 10 prespecified intervention types. We randomly selected two CBA and
two ITS studies from each review. Two researchers independently extracted information from the studies and the respective reviews.
Results: Sixty-nine reviews considered CBA and ITS studies for inclusion. We analyzed 21 CBA and 16 ITS studies from 11 to 8 re-
views, respectively. Cochrane reviews inconsistently defined and labeled CBA and ITS studies. Many studies did not meet the Cochrane
definition or the minimum criteria provided by Cochrane Effective Practice and Organisation of Care. The studies present a heterogeneous
set of study features and applied a large variety of analyses.
Conclusion: While CBA and ITS studies represent important study designs to evaluate the effects of interventions, especially on a pop-
ulation or organizational level, unclear study design features challenge unequivocal classification and appropriate use. We discuss options
for more specific definitions and explicit criteria for CBA and ITS studies.  2017 Elsevier Inc. All rights reserved.
Keywords: Controlled before-after studies; Interrupted time series analysis; Review; Methods; Public health; Nonrandomised study designs
1. Introduction
One key element of evidence-informed health care and
public health is that treatment and policy decisions are
informed by the best available scientific evidence [1]. De-
cisions are ideally guided by well-conducted systematic
reviews that gather evidence from well-conducted primary
studies to assess whether an intervention is more effective
and preferably also less costly than another intervention.
Interventions in the field of public health, health services,
health systems, and health policy tend to be more difficult to
evaluate than clinical interventions [2e4]. In these fields
especially, it may not be possible to conduct randomized
controlled trials (RCTs) for reasons of feasibility (e.g., inter-
ventions to reduce ambient air pollution [5]), ethical consid-
erations (e.g., home-based palliative care [6]), or lack of
political will [7]. Consequently, assessments of effectiveness
in such cases often have to rely on nonrandomized studies
[8,9]. Among these, interrupted time series (ITS) and
controlled before-after (CBA) studies are the study designs
most commonly included in Cochrane reviews [10].
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What is new?
Key findings
 CBA and ITS studies are increasingly used but
inconsistently labeled and defined in Cochrane
reviews.
What this adds to what was known?
 Variable definitions and unclear key characteristics
challenge their identification and classification as
well as distinction from other study designs.
What is the implication and what should change
now?
 We detail and explain CBA and ITS study charac-
teristics and propose steps toward a consensus pro-
cess to define key characteristics of these two study
designs.
A CBA study is defined in the Cochrane Handbook as a
study in which observations are made before and after the
implementation of an intervention, both in a group that re-
ceives the intervention and in a control group that does not
[11]. The Cochrane Effective Practice and Organisation of
Care (EPOC) Group, based on a long experience in consid-
ering nonrandomized studies, has developed criteria for in-
clusion of CBA studies in systematic reviews, to ensure a
minimum level of methodological rigor [12]. They recom-
mend at least two intervention sites and two control sites
[12], as well as contemporaneous data collection [13].
While the methodological literature on CBA studies is
limited, there is disagreement as to whether a key character-
istic of a CBA study is that the investigator has no control
over the intervention allocation [11,12,14,15]. Incoherent
use of terminology leads to a lack of differentiation between
features of CBA studies and other study designs, such as
nonrandomized controlled trials (NRCTs) [8,10,15,16].
An ITS study is defined in the Cochrane Handbook as a
study that uses observations at multiple time points before
and after an intervention (the ‘‘interruption’’). The design
attempts to detect whether the intervention has had an ef-
fect significantly greater than any underlying trend over
time [11,12]. The study is frequently conducted retrospec-
tively using routine data [17,18], and usually, there is no
investigator control over the allocation of the intervention
[11,12]. Cochrane EPOC specifies minimum criteria that
ITS studies must use at least three data points before and
three after the intervention and clearly define the point in
time when the intervention occurred [12].
Several papers have examined the use of ITS studies in
health research with respect to methodological aspects
[16,19e24]. It was noteworthy that ITS studies applied
inappropriate methods for statistical analysis, which led
to the frequent judgment of statistically nonsignificant ef-
fects as significant [19].
Clarity about CBA and ITS studies in terms of design,
data collection, and data analysis would be helpful for re-
searchers wishing to conduct a CBA or ITS study and facil-
itate a common terminology. Likewise, improved knowledge
and transparency about these study designs would make it
easier to search for and include these study designs in sys-
tematic reviews [25]. Ultimately, decision makers will have
more certainty to recommend for or against an intervention
based on studies that generate valid findings [26].
The objective of this study was therefore to examine the
application, design, and analysis characteristics of CBA and
ITS studies included in Cochrane reviews. We based our
analysis on the Cochrane database because it is a generally
accepted point of reference for evidence-informed deci-
sion-making in health and because it applies relatively ho-
mogenous standards in terms of study design terminology.
1.1. Primary question
What are the characteristics of CBA and ITS studies
included in Cochrane reviews in terms of design, conduct,
and analysis?
1.2. Secondary questions
Which types of interventions are assessed by Cochrane
reviews that consider and identify CBA and ITS studies?
How are CBA and ITS studies defined by review authors?
How are CBA and ITS studies (as defined by Cochrane au-
thors) defined and labeled by primary study authors?
2. Methods
2.1. Identification and analysis of systematic reviews
including CBA and ITS studies
Ijaz et al. [10] documented the use of CBA and ITS
studies as well as other nonrandomized studies in Cochrane
reviews up to May 2012. As we expected the conduct of
CBA and ITS studies in primary research as well as their in-
clusion in systematic reviews to have increased in recent
years, we updated the search by Ijaz et al. replicating their
methods. An a priori protocol of our study is available on-
line. Our search sought to identify reviews published be-
tween May 2012 and March 2015, whose authors
explicitly used the terms ‘‘controlled before-after’’ or CBA
and ‘‘interrupted time series’’ or ITS studies (i.e., merely
‘‘before-after studies’’ or ‘‘time series’’ were excluded).
For all reviews including nonrandomized studies, one
author (S.P.) extracted information with cross-checks per-
formed by two further authors (E.A.R. and D.P.). Informa-
tion was extracted on (1) type of study designs included and
number of studies identified for each type; (2) responsible
Cochrane group; (3) definition of CBA and/or ITS study
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by review authors; (4) risk of bias/quality appraisal tool and
assessment used by review authors; (5) level of intervention
(i.e., population, organizational, and individual level); and
(6) type of health intervention. While descriptions and def-
initions are often used interchangeably, reviews may state
criteria without a clear notion of the features of the study
design they refer to. This is why we also specifically exam-
ined whether reviews provided definitions.
We prespecified and defined 10 intervention types. We
based this on a previous publication, where we had made
a first pragmatic attempt toward a classification of public
health interventions [4]. These included behavioral/educa-
tional, clinical, environmental, health policy, health system,
nutrition, occupational, pharmaceutical, screening, and
vaccination interventions (see Appendix A at www.
jclinepi.com for definitions). We examined the labeling
and descriptions of CBA and ITS studies as well as their
applications to different intervention types across the
included reviews.
2.2. Selection and analysis of CBA and ITS studies
As we were interested in obtaining insights regarding the
use of CBA and ITS studies across different areas of health,
we purposively selected two reviews per intervention type
from those reviews that had included at least two CBA or
two ITS studies. A minimum of two studies was considered
important to ensure a reasonable applicability of the study
designs to a given intervention type and a minimum degree
of representativeness in study conduct. For those interven-
tion types, where we had to choose among several options
(e.g., health systems), we chose reviews from different Co-
chrane groups and assessing different interventions. For
each selected systematic review, we randomly selected
two studies, using an online random choice generator
[27]. We undertook the selection process separately for
CBA and ITS studies.
For the selected CBA and ITS studies, two authors
(S.P., J.B., A.F., D.P., T.M., C.R., J.P.T.H., E.A.R.,
L.M.P.) independently extracted information onto a data
extraction form that was specifically developed for the
purposes of this study and pretested in five studies. The
data extraction form considered (1) publication character-
istics (i.e., year of publication, journal, country of study,
language of study, funding source, terminology/labeling,
and definitions); (2) application characteristics (i.e., study
objective, population, intervention, comparison and
outcome, type of intervention, level of intervention);
and (3) methodological characteristics covering study
design (e.g., setting, control, allocation, temporal design),
data collection (e.g., number of measurements, outcome
assessments, source of data, timing), and data analysis
(e.g., statistical methods, unit of analysis) and reported
strengths and weaknesses of study design. Results were
compared to achieve consensus, and uncertainties and
discrepancies were extensively discussed, if necessary
with the whole author team.
Using the extracted data across studies, we assembled
information on how CBA and ITS studies were defined
by primary study authors and, comparing design and anal-
ysis features, attempted to define key characteristics of both
study designs.
3. Results
3.1. Identification and analysis of systematic reviews
For the period May 2012 to March 2015, we found 136
Cochrane reviews (4.8% of a total of 2,861 Cochrane re-
views published in this time period) that considered non-
randomized studies for inclusion (Supplemental Table 1 at
www.jclinepi.com). The 136 reviews included a total of
1,956 studies; the most prevalent study designs according
to the labels employed by review authors are listed in
Table 1. Nineteen reviews identified no studies for inclusion.
Sixty-nine of the reviews explicitly considered CBA and
ITS studies for inclusion (see Appendix B at www.jclinepi.
com for a complete reference list). Among these, 18 re-
views identified at least two CBA studies (range: 2e30
CBA studies) and 16 reviews identified at least two ITS
studies (range: 2e52 ITS studies). Altogether, 12 reviews
identified both CBA and ITS studies. Additionally, five
and three reviews identified only one CBA and ITS study,
respectively.
3.1.1. Which types of interventions are assessed by
Cochrane reviews that consider and identify CBA and
ITS studies?
In our sample of 69 reviews, CBA and ITS studies were
most widely considered in reviews of health system
Table 1. Study designs among the 1,956 studies included in Cochrane
reviews that considered nonrandomized studies according to the
labels employed by review authors (May 2012eMarch 2015)
Label Number (percentage)
RCTs 597 (31)
Cohort studies 166 (9)
CBA 168 (9)
ITS 143 (7)
Cross-sectional studies 109 (6)
Controlled clinical trials (CCTs) 91 (5)
Uncontrolled before-after studies 76 (4)
Observational studies 75 (4)
Cluster RCT 65 (3)
Case control 60 (3)
Retrospective cohort studies 55 (3)
NRCT 42 (2)
Prospective controlled cohort studies 26 (1)
Prospective cohort studies 25 (1)
Abbreviations: RCT, randomized controlled trial; NRCT, non-
randomized controlled trial; CBA, controlled before-after; ITS, inter-
rupted time series.
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interventions (n 5 36), followed by reviews of behavioral
(n 5 8), environmental (n 5 6), occupational (n 5 5), clin-
ical (n 5 5), and health policy (n 5 4) interventions. They
were rarely or not at all considered in reviews of vaccina-
tion, screening, pharmaceutical, or nutrition interventions.
Among the reviews considering CBA and ITS studies, 12
were targeting the population, 43 the organizational, and
14 the individual level. Tables 2 and 3 show how CBA
and ITS studies have recently been applied in reviews that
actually identified these study designs, suggesting that both
study designs are most frequent in reviews of health system
interventions directed at an organizational level. We
included CBA and ITS studies that derived from the same
reviews [28,29].
3.1.2. How are CBA and ITS studies defined by review
authors?
About a third of the 69 reviews considering both CBA
and ITS studies reported the EPOC criteria of two interven-
tion and two control sites (43%) for CBA studies and three
data points before and three after intervention and a clearly
defined intervention time point (36%), respectively, for ITS
studies (Fig. 1). For CBA studies, many also referred to
‘‘contemporaneous data collection’’ and/or ‘‘an appropriate
choice of control’’; the need for ‘‘same time periods before
and after the intervention’’ was also specified repeatedly.
For ITS studies, 25% of reviews described one of the two
EPOC criteria, mostly omitting a clearly defined interven-
tion time point. Less than a tenth of all reviews (4% for
CBA and 7% for ITS studies) referred to EPOC criteria
for CBA or ITS studies without stating them.
Among the seven reviews that provide specific defini-
tions for CBA studies, two reported the Cochrane Hand-
book definition [11] together with the EPOC criteria
[30,31] and another two referred to ‘‘prospective cohort
studies’’ [32,33]. Four of the five reviews that provided def-
initions for ITS studies reported them together with the
EPOC criteria. Two reviews explicitly referred to the Co-
chrane Handbook definition for ITS studies [30,31].
3.2. Selection and analysis of primary studies
For the analysis of CBA studies, we purposively selected
11 reviews, covering two reviews each for behavioral, envi-
ronmental, health policy, and health system interventions
and one review each for nutrition, occupational, and
screening interventions. Among the 22 CBA studies, we
randomly selected from these reviews, one study (from
the screening review) was excluded postselection due to
an initial misclassification (i.e., it was identified as a
CBA study at abstract level, but the review authors labeled
the study in the risk of bias assessment as a CCT) [34]. For
the analysis of ITS studies, we selected eight reviews, two
each concerned with behavioral, health policy, health sys-
tem, and occupational interventions. Random selection of
two studies from each review yielded 16 ITS studies.
3.2.1. How are CBA and ITS studies labeled or defined
by primary study authors?
Primary study authors did not label any study ‘‘CBA.’’
The descriptions of CBA labels shown in Table 4 were
often mentioned in combination with ‘‘before and after
the intervention.’’ Primary study authors labeled their study
as an ‘‘ITS’’ in only one study. All other studies used
various descriptions with ‘‘time series’’ mentioned most
often in combination with ‘‘analysis’’ or ‘‘design.’’ None
of the included studies gave a definition of the study
design.
Table 2. Characteristics of reviews including CBA studies according to intervention type, level, responsible Cochrane group, and number of studies
identified (May 2012eMarch 2015)
Intervention type (number of reviews)
Cochrane group
(number of reviews) Population level Organizational level Individual level
Number of
CBA studies









Health policy (1) OSH (1) 1 3
Environmental (2) PH (1)
ARI (1)
1 1 13
Occupational (2) Injuries (1)
OSH (1)
2 20
Clinical (1) PAPAS (1) 1 2
Nutrition (1) DPLP (1) 1 11
Screening (1) PAPAS (1) 1 2
Pharmaceutical, vaccination (0) d
Abbreviations: ARI, acute respiratory infections; CBA, controlled before-after; DA, drugs and alcohol; DPLP, developmental, psychosocial and
learning problems; EPOC, Effective Practice and Organisation of Care; OSH, occupational safety and health; PH, public health; PAPAS, pain, palli-
ative and supportive care.
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3.2.2. What are the characteristics of CBA and ITS
studies included in Cochrane reviews in terms of design,
conduct and analysis?
3.2.2.1. CBA studies. Among the 21 selected CBA studies,
five were not CBA studies according to the Cochrane defi-
nition (Fig. 2) because they lacked control sites [35,36] or
measurements before the intervention [37e39]; in one
study, hospital units were randomized into control and
intervention group and we therefore classified it as a cluster
RCT [40]. Of the 16 actual CBA studies, nine fulfilled the
EPOC criteria (i.e., two intervention and two control sites,
contemporaneous data collection). Compared to the Co-
chrane Handbook, Cochrane EPOC provides a more spe-
cific definition of a CBA study where the investigators do
not have control over the intervention allocation. If we
adopt this more specific definition of the selected 16
Table 3. Characteristics of reviews including ITS studies in terms of intervention type, level, responsible Cochrane group, and number of studies
identified (May 2012eMarch 2015)
Intervention type (number of reviews)
Cochrane group
(number of reviews) Population level Organizational level Individual level
Number of ITS
studies




















Abbreviations: DA, drugs and alcohol; EPOC, Effective Practice and Organisation of Care; OSH, occupational safety and health; PH, public
health; TA, tobacco addiction; ITS, interrupted time series.
Fig. 1. Criteria for CBA and ITS studies as used in Cochrane reviews. CBA, controlled before-after; ITS, interrupted time series; EPOC, Effective
Practice and Organisation of Care.
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CBA studies, six complied with both the EPOC definition
and criteria.
Table 5 presents a selection of further study design and
analysis characteristics (see Supplemental Table 2 at www.
jclinepi.com for an extended version). There was approxi-
mately equal use of CBA studies undertaken in a prospec-
tive or retrospective manner. We defined retrospective as a
study, in which outcome data collected prior to the study
period are used. In contrast, prospective studies collect
outcome data during the study period. Defining studies as
retrospective or prospective was, however, quite chal-
lenging [8] and judgments may vary. For about half of
the selected studies, allocation of the intervention was not
controlled by the investigators. The median number of sites
among studies classified as EPOC CBA studies according
to design was 7.5 (range: 3e748) for intervention and 5
(range: 3e8,301) for control sites. In some cases, the defi-
nition of ‘‘sites’’ was unclear and appeared to be synony-
mous with individuals (e.g., [47]). Study authors used a
variety of mostly inappropriate or inefficient statistical
analysis methods. Many studies applied simple statistical
analysis methods, such as simple t-tests and did not take
clustering into account, leading to unit of analysis errors
and imprecision of confidence intervals. Studies performed,
for example, a simple before and after comparison in the
intervention group only or compared postmeans of individ-
ually aggregated data into intervention and control group.
3.2.3. ITS studies
Of the 16 selected ITS studies, two did not meet the Co-
chrane definition, as they did not include any data before the
intervention [56,57] (Fig. 2). Of the 14 actual ITS studies,
one did not comply with the EPOC criteria (i.e., at least three
data points before and after the interruption and a clearly
defined intervention time point), due to an insufficient num-
ber of data points before the intervention. Of the 13 ITS
studies complying with EPOC design criteria, five did not
perform a statistical analysis and merely displayed the re-
sults graphically or reported means before and after the
intervention. We identified one study, where the intervention
was under control of the investigators [58]. This study was,
however, different in many ways, as the review authors
lumped together several ‘‘meth studies’’ [35,58] and
included them as a single ITS study [28].
As shown in Table 6 (see Supplemental Table 3 at
www.jclinepi.com for an extended version), one study
applied autoregressive integrated moving average (ARI-
MA) and at least two studies applied segmented regression
analysis, although bad reporting impeded a clear identifi-
cation. A majority of studies conducted some form of
regression analysis and some adjusted or tested for auto-
correlation (n 5 6) and/or reported to adjust for secular
trend (n 5 6). Eight ITS studies [57,63,65e71] from five
reviews were reanalyzed by review authors as recommen-
ded by EPOC in case of an inappropriate analysis. For ITS
studies adhering to EPOC design criteria, the median num-
ber of data points was 12 (range: 3e46) before and 12
(range: 3e86) after the intervention. Three studies had a
control group, and we therefore classified them as
controlled ITS studies [61,62,71]. All studies were con-
ducted retrospectively.
Table 4. Labels of CBA and ITS studies in primary studies
CBA labels ITS labels
Quasiexperimental (n 5 5) Time series analysis/design
(n 5 5)
Survey (n 5 4) Observational (n 5 3)
Comparative study (n 5 3) Analysis (n 5 3)
Observational (n 5 2) Difference in difference (n 5 2)
Cross-sectional (n 5 2) Retrospective (n 5 2)
Natural experimental (n 5 2) Surveys (n 5 1)
Case control (n 5 1) Interrupted time series (n 5 1)
Prospective cohort (n 5 1) Natural experimental
research (n 5 1)
Difference in difference (n 5 1)
Abbreviations: CBA, controlled before-after; ITS, interrupted time
series.
Fig. 2. EPOC criteria assessment for CBA and ITS studies. CBA, controlled before-after; ITS, interrupted time series; EPOC, Effective Practice and
Organisation of Care.
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4. Discussion
4.1. Key findings
In relation to our primary research question, we found a
heterogeneous set of different study designs under the label
‘‘CBA’’ and ‘‘ITS’’ studies. Not all studies fitted the Co-
chrane definition of a CBA and ITS study. We found, for
example, CBA studies without control sites as well as
ITS studies without an intervention (‘‘the interruption’’)
included in Cochrane reviews. Some CBA studies did not
comply with the EPOC criteria, for example, because of
an insufficient number of intervention and control sites;
one ITS study had insufficient data points. Researchers
were involved in the intervention allocation in almost half
of all included CBA studies. According to EPOC guidance,
such studies should be classified as NRCTs. It is also note-
worthy that there is a stark discrepancy between methods
employed for data collection vs. data analysis, where re-
searchers often do not fully exploit the strength of the
collected data in their analysis. Bad reporting, however,
often precluded clear identification of the analysis methods.
In relation to our secondary research questions, most Co-
chrane reviews that included CBA and ITS studies were con-
cerned with interventions on an organizational level; few
addressed interventions on a population level, and as expected,
very few tookplaceonan individual level.Wedidnotfindmany
reviews of typical public health interventions, for example,
environmental, vaccination, or screening interventions, which
would lend themselves to the use of CBA and ITS studies.
There are striking differences among Cochrane reviews
with respect to labeling and defining CBA and ITS studies.
One-third of the included reviews did not provide any
criteria for the study designs. These findings were all the
more surprising, given that our sample was drawn from
the relatively homogeneous and strongly methodologically
influenced Cochrane community. Our analysis thus con-
firms that the inconsistent use of terminology leads to
confusion among systematic reviewers regarding what can
be classified as an ITS or CBA study [8,21,72,73].
On the primary study level, the labels ‘‘CBA’’ and
‘‘ITS’’ appear infrequently; instead, a large variety of terms
is used. This suggests that CBA and ITS study labels and
the study design characteristics associated with them are
hardly used or known among primary study authors.
4.2. Toward clearer CBA and ITS study definitions and
criteria
Considering the challenges we faced trying to categorize
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Abbreviations: CBA, controlled before-after; Retr., retrospective; Prosp., prospective; NR, not reported; Na, not applicable.
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considering the limited use of the study design labels in pri-
mary research, we explain in detail study characteristics
and potentially problematic features.
This discussion is intended to help review authors iden-
tify these study designs in the screening process; from our
experience, the definitions and criteria provided by Co-
chrane and Cochrane EPOC, while helpful, still leave much
space for interpretation, a lack of clarity that is partially
responsible for the heterogeneous findings of this study
and previous studies [10,15,16,19,20]. This discussion is
also intended to offer input toward consensual definitions
and features of these study designs, which would eventually
be helpful for both review authors and primary researchers.
4.2.1. CBA studies
4.2.1.1. Key characteristics. According to EPOC and with
some additional elaboration, a high-quality CBA study (1)
uses at least two intervention and two appropriate control
sites and (2) employs contemporaneous data collection,
whether carried out specifically for this purpose or using
existing datasets, at relevant preintervention and postinter-
vention time points at all sites. CBA studies may be pro-
spective or retrospective in nature. The intervention
effects can be analyzed at cluster or individual level, but
the analysis should compare the difference in prechange
and postchange between intervention and control groups.
4.2.1.2. Explanations. Using two intervention and two
control sites may be advantageous because study validity
increases with more sites being used. With only one site
per group, any difference in observed effect between the
intervention and control group may simply be due to under-
lying differences in the characteristics of the two sites,
where these characteristics may be measured, known but
not measured or unknown. In circumstances, when more
than two levels are involved, for example, individuals or
classes nested within schools and cities, it may be chal-
lenging to decide what constitutes the site [74]. Further-
more, should sites be actual locations (e.g., villages,
schools) or can other clusters or groups of people (e.g.,
family members in a household or employees in a given
company) form a site? This may, however, be irrelevant
as long as the analysis takes the groups into account. The
sites should have similar baseline characteristics, by choice
or through matching; in case of baseline differences, an
appropriate method of statistical adjustment should be
applied.
Whereas Cochrane EPOC [12] and Hartling et al. [15]
acknowledge CBA studies as natural experiments, in the
Cochrane handbook, investigator control to some extent is
not ruled out [11]. Deeks et al. [14] suggest that a CBA
‘‘can also be considered an experimental design if the
investigator has control over or can deliberately manipulate
the introduction of the intervention.’’
The analysis should take into account the presence of a
control group. A simple t-test comparing postchanges be-
tween the groups may not suffice to show an intervention
effect, particularly where baseline differences between the
groups exist. The analysis should adjust for potential clus-
tering effects where unit of observation and unit of analysis
differ. More advanced methods, such as difference-in-
























































Abbreviations: ITS, interrupted time series; RCT, randomized controlled trial.
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different sites, may better reflect the design. Such analysis
methods have been widely applied in other disciplines, such
as economics [75], and it would be beneficial to take on-
board lessons learnt.
4.2.1.3. Differences and similarities in relation to other
study designs. CBA studies partially overlap with other
study designs with implications for how these studies are
searched for, described, and appraised as well as synthe-
sized in systematic reviews. The main difficulty lies in
differentiating between cluster NRCTs and CBA studies.
One possibility is to use active intervention allocation by
the investigator as the distinguishing feature between clus-
ter NRCTs (present) and CBA studies (absent; natural
experiment); this approach has been adopted by Cochrane
EPOC [12]. There are, however, cases where such a differ-
entiation is difficult due to poor reporting and various inter-
pretations of what to consider a natural experiment.
Interestingly, Shadish et al. [76] do not distinguish between
specific study design labels when describing ‘‘quasiexperi-
mental designs that use both control groups and pretests.’’
Acknowledging CBA studies and cluster NRCTs as part
of a broader study design group without the necessity to
identify the design more specifically may be another way
forward. Differences in study design features could thus
be articulated as part of the risk of bias assessment rather
than as part of the study classification.
4.2.2. ITS studies
4.2.2.1. Key characteristics. ITS studies are usually de-
signed as natural experiments. They may be prospective or
retrospective in nature and may include a control group
(controlled ITS) [8,15,22]. Asmentioned byCochraneEPOC,
ITS studies should (1) use at least three data points before and
three after the intervention and (2) clearly define the point in
time, when the intervention occurred. An appropriate statisti-
cal analysis includes adjustment for secular trend.
4.2.2.2. Explanations. Although ITS studies are usually
defined as natural experiments [12,15], ITS studies can be
used to assess interventions allocated by the investigators
[77]. The EPOC threshold of three data points before and
after the intervention is based on the reasoning that drawing
a line through any fewer than three data points would esti-
mate trend in a very unreliable way. Indeed, several recent
studies suggest that sufficient statistical power is only
achieved when at least eight data points are included; even
more may be required when using ARIMA or segmented
regression analysis [22,24,78]. Generally speaking, the pre-
cision of ITS studies increases with the number of data
points. An unequivocal distinction between preintervention
and postintervention and implementation time periods is
critical; this also refers to multiple interventions imple-
mented sequentially or staggered implementation of a given
intervention in different groups, institutions, or geograph-
ical areas [22]. Adding a control group further enhances
the study’s validity and minimizes risk of bias [79]:
whereas an ITS study compares the postintervention trend
with a counterfactual (i.e., the prediction of what would
have happened in case the intervention had not taken place
estimated from preintervention trends), a controlled ITS
study compares preintervention and postintervention time
trends between an intervention and control group. Visuali-
zation of data can help the reader interpret the study results
[22,23,80] but can also be misleading and should therefore
not be used routinely as a means of identifying or
measuring an effect [81].
The discrepancies between data collection and analysis
in the included ITS studies highlight the importance of a
statistical analysis that adjusts for secular trend
[17,19,22,24]. ARIMA or segmented regression models,
which recognize secular trend as well as autocorrelation,
are considered highly appropriate for analyzing ITS data
[19,24,80,82]; other regression analyses may also be appro-
priate. Studies whose statistical analysis does not explicitly
acknowledge secular trend (e.g., comparison of preinterven-
tion and postintervention means) or that merely display re-
sults graphically in fact miss the most important strength of
the ITS design. EPOC allows ITS studies with inappropriate
analysis to be included in systematic reviews, provided the
data are reanalyzed. This relies, however, partly on primary
study authors providing their original data and is a time-
consuming and resource-intensive process.
4.2.2.3. Differences and similarities in relation to other
study designs. ITS studies are sometimes interchangeably
listed as ‘‘time series.’’ However, a time series merely in-
vestigates an ordered sequence of values of a variable at
equally spaced time intervals [83], whereas an ITS study
is characterized by an interruption. ITS studies are also
closely related to repeated measures studies, where mea-
surements are made in the same individuals at each time
point [12]. A further related study design is the regression
discontinuity design, where different temporal occasions
can be assigned to different treatment conditions [84].
Especially with respect to controlled ITS studies, it may
be hard for systematic reviewers to label these as an ITS
study vs. a CBA study. As mentioned above, the essential
feature of an ITS study is the statistical analysis, which
must reflect multiple measurements over time and adjust
for important secular trends. If this is not the case, a
controlled ITS, with multiple measurements before and af-
ter the intervention, may be considered as a CBA study.
4.3. Strengths and weaknesses of this study
We analyzed a sample of CBA and ITS studies included
in recent Cochrane reviews with respect to application and
specific methodological characteristics. The sample was in-
tended to be somewhat representative of the prespecified
types of interventions. Representativeness of findings is,
however, limited, as we only selected two reviews per
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intervention type (where available) and two included
studies from the selected reviews.
At the primary study level, data extraction was done in
duplicate and difficulties were extensively discussed
among the data extractors and, where necessary, with the
whole author team. As we did not reanalyze the studies,
our insights reflect CBA and ITS studies as originally con-
ducted, analyzed, and reported rather than according to
their potential. In fact, we did not contact study authors
for missing study details. Finally, the generalizability of
our findings is probably limited to Cochrane reviews; we
would expect to find even more variation in methodolog-
ical characteristics of CBA and ITS studies outside of
Cochrane.
4.4. Recommendations for research and practice
CBA and ITS studies are increasingly being recognized
as important study designs that, if conducted and analyzed
well, can provide reliable effect estimates of the impacts of
interventions, where randomization is not feasible. Impor-
tantly, there is a need to further the understanding of the
definitions and key characteristics of these study designs
among primary researchers and systematic reviewers,
including through textbooks of epidemiology and epidemi-
ological curricula and beyond the field of epidemiology.
Recently published research provides the first detailed
guidance on how to conduct ITS studies [85]. However,
CBA studies in particular almost appear to be ‘‘artificial
study designs,’’ with the label created by systematic re-
viewers but little used in the primary research world. More
specific definitions and key characteristics would be bene-
ficial for systematic review authors inside and outside of
Cochrane to facilitate greater clarity with respect to
including or excluding study designs. Further discussions
should clarify when to include a CBA or ITS study accord-
ing to EPOC criteria and when to include a study not
meeting EPOC criteria but downgrade for risk of bias. This
would minimize confusion and improve consistency within
Cochrane and beyond.
While we have summarized and explained important
features and characteristics of CBA and ITS studies and
initiated a discussion about key characteristics, key study
design and analysis characteristics should be clarified and
their definitions updated through a consensus process, such
as a Delphi procedure. There are direct implications for risk
of bias assessment for these study designs that will be
developed as the ROBINS-I tool [86] is advanced for
different study designs. The development of a new report-
ing guideline, for example, an extension of the Transparent
Reporting of Evaluations with Nonrandomized Designs
statement [87], could be an important second step. Taken
together, this could greatly advance methodological prac-
tice at primary study as well as systematic review level
and ensure that CBA and ITS studies are put to the best
use possible in evaluating the impacts of interventions.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2017.07.008.
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1 Review ID 
(AU+YR) 
Title 
de Jong 2012 Mobile phone messaging for facilitating self-management of long-term illnesses 
Adams 2015 Lipid-lowering efficacy of atorvastatin 
Akl 2013 Educational games for health professionals 
Siegfried 2014 Restricting or banning alcohol advertising to reduce alcohol consumption in adults and 
adolescents 
Allen 2013 Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for 
assessing the resectability with curative intent in pancreatic and periampullary cancer 
Anglemeyer 2013 Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples 
Anglemeyer 2014 Treatment of Kaposi sarcoma in children with HIV-1 infection 
Atherton 2012 Email for clinical communication between patients/caregivers and healthcare 
professionals 
Taylor 2014 Computed tomography (CT) angiography for confirmation of the clinical diagnosis of 
brain death 
Aubin 2012 Interventions to improve continuity of care in the follow-up of patients with cancer 
Baalbergen 2013 Primary surgery versus primary radiotherapy with or without chemotherapy for early 
adenocarcinoma of the uterine cervix 
Curti 2015 Interventions to increase the reporting of occupational diseases by physicians 
Bala 2013 Mass media interventions for smoking cessation in adults 
Acosta 2014 Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing 
policies 
Barte 2014 Yellow fever vaccine for patients with HIV infection 
Beller 2015 Palliative pharmacological sedation for terminally ill adults 
Benathar 2012 Medical and surgical treatment for ocular myasthenia 
Brocklehurst 
2013 
The effect of different methods of remuneration on the behaviour of primary care 
dentists 
Bromley 2014 Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child 
Henderson 2015 Provision of a surgeon's performance data for people considering elective surgery 
Brusamento 2012 Male involvement for increasing the effectiveness of prevention of mother-to-child HIV 
transmission (PMTCT) programmes 
Meyer 2012 Email for communicating results of diagnostic medical investigations to patients 
Cirocchi 2012 Non-resection versus resection for an asymptomatic primary tumour in patients with 
unresectable stage IV colorectal cancer 
Cirocchi 2012 Radiofrequency ablation in the treatment of liver metastases from colorectal cancer 
Clement 2013 Mass media interventions for reducing mental health-related stigma 
Coppo 2014 School policies for preventing smoking among young people 
Algie 2015 Interventions for reducing wrong-site surgery and invasive procedures 
Dangour 2013 Interventions to improve water quality and supply, sanitation and hygiene practices, and 
their effects on the nutritional status of children 
Davey 2013 Interventions to improve antibiotic prescribing practices for hospital inpatients 
Harrod 2014 Interventions for primary prevention of suicide in university and other post-secondary 
educational settings 
Hardt 2013 Lateral pararectal versus transrectal stoma placement for prevention of parastomal 
herniation 
Dyer 2014 Dental auxiliaries for dental care traditionally provided by dentists 
Eliakim-Raz 2013 Influenza vaccines in immunosuppressed adults with cancer 
Ballini 2015 Interventions to reduce waiting times for elective procedures 
Fiander 2015 Interventions to increase the use of electronic health information by healthcare 
practitioners to improve clinical practice and patient outcomes 
Rolfe 2014 Interventions for improving patients' trust in doctors and groups of doctors 
Fonner 2012 Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in 
developing countries 
Galvagno 2013 Helicopter emergency medical services for adults with major trauma 
Gbabe 2014 Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults 
Gentry 2013 Telephone delivered interventions for reducing morbidity and mortality in people with 
HIV infection 
Kendrick 2012 Home safety education and provision of safety equipment for injury prevention 
Flodgren 2013 Interventions to improve professional adherence to guidelines for prevention of device-
related infections 
Glenny 2013 Antibiotics for the prophylaxis of bacterial endocarditis in dentistry 
Kendrick 2013 Parenting interventions for the prevention of unintentional injuries in childhood 
Gillaizeau 2012 Computerized advice on drug dosage to improve prescribing practice 
Vodopivec-
Jamsek 2012 
Mobile phone messaging for preventive health care 
Goyder 2015 Email for clinical communication between healthcare professionals 
Gurumurthy 2014 Effectiveness of different treatment modalities for the management of adult-onset 
granulosa cell tumours of the ovary (primary and recurrent) 
Hanchard 2013 Physical tests for shoulder impingements and local lesions of bursa, tendon or labrum 
that may accompany impingement 
Muckle 2012 Managed alcohol as a harm reduction intervention for alcohol addiction in populations 
at high risk for substance abuse 
Haroutiiunian 
2012 
Methadone for chronic non-cancer pain in adults 
Gurol-Uranci 
2012 
Mobile phone messaging for communicating results of medical investigations 
Pani 2013 QTc interval screening for cardiac risk in methadone treatment of opioid dependence 
McCleery 2015 Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies 
Henschke 2013 Red flags to screen for malignancy in patients with low-back pain 
Henson 2013 Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing 
radical pelvic radiotherapy 
Gomes 2013 Effectiveness and cost-effectiveness of home palliative care services for adults with 
advanced illness and their caregivers 
Hunt 2015 Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for 
traumainduced coagulopathy in adult trauma patients with bleeding 
Brown 2014 Centre-based day care for children younger than five years of age in low- and middle-
income countries 
Baker 2015 Community wide interventions for increasing physical activity 
Jefferson 2012 Vaccines for preventing influenza in healthy children 
Jefferson 2014 Vaccines for preventing influenza in healthy adults 
Hughes 2013 Infection control strategies for preventing the transmission of meticillin-resistant 
Staphylococcus aureus (MRSA) in nursing homes for older people 
Jin 2012 Dietary flavonoid for preventing colorectal neoplasms 
Tusting 2013 Mosquito larval source management for controlling malaria 
Hayes 2012 Collaboration between local health and local government agencies for health 
improvement 
Jia 2014 Strategies for expanding health insurance coverage in vulnerable populations 
Kredo 2013 Decentralising HIV treatment in lower- and middle-income countries 
Kredo 2014 Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral 
therapy 
Khangura 2012 Primary care professionals providing non-urgent care in hospital emergency 
departments 
Jayaraman 2014 Advanced training in trauma life support for ambulance crews 
Rutebemberwa 
2014 
Financial interventions and movement restrictions for managing the movement of 
health workers between public and private organizations in low- and middle-income 
countries 
Kristjansson 2015 Food supplementation for improving the physical and psychosocial health of socio-
economically disadvantaged children aged three months to five years 
Lazzerini 2013 Specially formulated foods for treating children with moderate acute malnutrition in 
low- and middle-income countries 
Legare 2014 Interventions for improving the adoption of shared decision making by healthcare 
professionals 
Webster 2014 Exit interviews to reduce turnover amongst healthcare professionals 
Lindegren 2012 Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and 
family planning services 
Lip 2014 Anticoagulation versus placebo for heart failure in sinus rhythm 
Liu 2014 Reminder systems to improve patient adherence to tuberculosis clinic appointments for 
diagnosis and treatment 
Lopez 2012 Steroidal contraceptives and bone fractures in women: evidence from observational 
studies 
Lewis 2014 Physician anaesthetists versus non-physician providers of anaesthesia for surgical 
patients 
Maeda 2013 Perianal injectable bulking agents as treatment for faecal incontinence in adults 
Maguire 2014 Antidepressants for people with epilepsy and depression 
Martlew 2014 Psychological and behavioural treatments for adults with non-epileptic attack disorder 
Lawrie 2013 Laparoscopy versus laparotomy for FIGO stage I ovarian cancer 
McRobbie 2014 Electronic cigarettes for smoking cessation and reduction 
Lavoie 2014 Devices for preventing percutaneous exposure injuries caused by needles in healthcare 
personnel 
Gupta 2012 Electric fans for reducing adverse health impacts in heatwaves 
Montero 2014 Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant 
recipients 
Maaskant 2015 Interventions for reducing medication errors in children in hospital 
Moran 2013 Effectiveness of systematic screening for the detection of atrial fibrillation 
Rooney 2013 Pharmacological treatment of depression in patients with a primary brain tumour 
Atherton 2012 Email for the coordination of healthcare appointments and attendance reminders 
Murthy 2012 Interventions to improve the use of systematic reviews in decision-making by health 
system managers, policy makers and clinicians 
Mischke 2013 Occupational safety and health enforcement tools for preventing occupational diseases 
and injuries 
Pande 2013 The effect of pharmacist-provided non-dispensing services on patient outcomes, health 
service utilisation and costs in low- and middle-income countries 
Jayaraman 2014 Advanced trauma life support training for hospital staff 
Pavlov 2015 Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people 
with alcoholic liver disease 
Peckham 2013 Homeopathy for treatment of irritable bowel syndrome 
Omidvari 2013 Nutritional screening for improving professional practice for patient outcomes in 
hospital and primary care settings 
Poirot 2013 Mass drug administration for malaria 
Reda 2012 Healthcare financing systems for increasing the use of tobacco dependence treatment 
Parmelli 2012 Interventions to increase clinical incident reporting in health care 
Rizzuto 2013 Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility 
Pega 2013 In-work tax credits for families and their impact on health status in adults 
Reeves 2013 Interprofessional education: effects on professional practice and healthcare outcomes 
(update) 
Romano 2012 Exercises for adolescent idiopathic scoliosis 
Desapriya 2014 Vision screening of older drivers for preventing road traffic injuries and fatalities 
Ferri 2013 Media campaigns for the prevention of illicit drug use in young people 
Rockers 2013 Interventions for hiring, retaining and training district health systems managers in low- 
and middle-income countries 
Nava 2014 Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for 
Neuro-Behcet's Syndrome 




Preventing occupational stress in healthcare workers 
Sawmynaden 
2012 
Email for the provision of information on disease prevention and health promotion 
Siegfried 2013 Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive 
children aged 2 to 5 years old 
Sauni 2015 Remediating buildings damaged by dampness and mould for preventing or reducing 
respiratory tract symptoms, infections and asthma 
Smailagic 2015 (18)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other 
dementias in people with mild cognitive impairment (MCI) 
Smart 2014 Early referral to specialist nephrology services for preventing the progression to end-
stage kidney disease 
Steingart 2013 Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults 
Steingart 2014 Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults 
Lihua 2013 Spinal cord stimulation for cancer-related pain in adults 
Theron 2014 The diagnostic accuracy of the GenoType((R)) MTBDRsl assay for the detection of 
resistance to second-line anti-tuberculosis drugs 
Thomas 2013 Influenza vaccination for healthcare workers who care for people aged 60 or older living 
in long-term care institutions 
Tudor Car 2013 Telephone communication of HIV testing results for improving knowledge of HIV 
infection status 
Turley 2013 Slum upgrading strategies involving physical environment and infrastructure 
interventions and their effects on health and socio-economic outcomes 
Shrestha 2015 Workplace interventions for reducing sitting at work 
van der Molen 
2012 
Interventions to prevent injuries in construction workers 
van Ginneken 
2013 
Non-specialist health worker interventions for the care of mental, neurological and 
substance-abuse disorders in low- and middle-income countries 
van Velthoven 
2013 
Telephone delivered interventions for preventing HIV infection in HIV-negative persons 
Verbeek 2012 Interventions to prevent occupational noise-induced hearing loss 
Vinceti 2014 Selenium for preventing cancer 
Giguère 2012 Printed educational materials: effects on professional practice and healthcare outcomes 
(Review) 
Walshe 2013 Larvivorous fish for preventing malaria transmission 
Chan 2013 End-of-life care pathways for improving outcomes in caring for the dying 
Winfield 2014 Non-pharmaceutical management of respiratory morbidity in children with severe global 
developmental delay 
Young 2013 Post-exposure passive immunisation for preventing measles 
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The grey shaded area on the left includes the information depicted in Table 5 in the publication. The right part (in white) presents the additional information. 
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Supplemental Table 3 ITS study characteristics 
The grey shaded area on the left includes the information depicted in Table 5 in the publication. The right part (in white) presents the additional information. 
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Interrupted time series study 
found mixed effects of the impact 
of the Bavarian smoke‑free 
legislation on pregnancy outcomes
Stephanie Polus1,2*, Jacob Burns1,2, Sabine Hoffmann1,2, Tim Mathes3, Ulrich Mansmann1,2, 
Jasper V. Been4, Nicholas Lack5, Daniela Koller1,2, Werner Maier6 & Eva A. Rehfuess1,2
In 2007 the German government passed smoke‑free legislation, leaving the details of implementation 
to the individual federal states. In January 2008 Bavaria implemented one of the strictest laws in 
Germany. We investigated its impact on pregnancy outcomes and applied an interrupted time 
series (ITS) study design to assess any changes in preterm birth, small for gestational age (primary 
outcomes), and low birth weight, stillbirth and very preterm birth. We included 1,236,992 singleton 
births, comprising 83,691 preterm births and 112,143 small for gestational age newborns. For most 
outcomes we observed unclear effects. For very preterm births, we found an immediate drop of 10.4% 
(95%CI − 15.8, − 4.6%; p = 0.0006) and a gradual decrease of 0.5% (95%CI − 0.7, − 0.2%, p = 0.0010) after 
implementation of the legislation. The majority of subgroup and sensitivity analyses confirm these 
results. Although we found no statistically significant effect of the Bavarian smoke‑free legislation on 
most pregnancy outcomes, a substantial decrease in very preterm births was observed. We cannot 
rule out that despite our rigorous methods and robustness checks, design‑inherent limitations of 
the ITS study as well as country‑specific factors, such as the ambivalent German policy context have 
influenced our estimation of the effects of the legislation.
Over the past two decades, a range of policies and programmes at global, national and regional levels have been 
designed to reduce the detrimental harms associated with tobacco  use1,2. There is strong evidence that smoke-free 
legislation improves adult health outcomes, such as cardiovascular health and mortality from smoking-related 
 illnesses3. There is also evidence that smoke-free legislation improves pregnancy outcomes and child  health3,4. 
For example, a recent systematic review found reductions in preterm birth rates, perinatal mortality and hospital 
attendance rates for asthma following smoke-free  legislation4. However, findings are not fully consistent and 
based on less rigorous study  methods3,4, and more rigorous studies are needed to strengthen the evidence  base5.
Since ratification of the World Health Organization (WHO) Framework Convention on Tobacco Control 
(FCTC) in 2004, Germany is obliged by international law to implement appropriate measures to reduce and 
prevent tobacco consumption and second-hand smoke (SHS)  exposure6. Germany prohibited smoking in the 
workplace in  20047. In 2007 a national law was passed to protect non-smokers from the harmful consequences 
of SHS and required the implementation of federal state level legislation to prohibit smoking in public  places8. 
Sargent et al.9 investigated the short-term effects of the smoke-free legislation on the national level and found a 
significant decrease in hospital admissions due to acute coronary events after implementation of the smoke-free 
legislation. No study, however, has assessed the effects of the smoke-free legislation on pregnancy outcomes in 
the German context.
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In this study, we assess the impact of the smoke-free legislation on pregnancy outcomes implemented on 1 
January 2008 in Bavaria, Germany’s largest and second most populous state with more than 12.5 million inhabit-
ants and approximately one-sixth of all births in  Germany10.
Results
There were 1,290,487 deliveries between 1 January 2005 and 31 December 2016. Due to the standardized data 
collection process related to Bavarian hospital births, there are no missing data of hospital births. We excluded 
53,495 births (4.15%) because inclusion criteria were not met (see Fig. 1). The analysed time series thus included 
1,236,992 singleton deliveries, which represents a monthly mean of 8,950 births (range 7,266–10,825). The 
number of births per month increased steadily over the last 5 years of the study period (see Supplementary 
Fig. S1 online).
Overall, there were 83,691 preterm births (< 37 gestational weeks) during the study period. During the same 
time span there were 112,143 babies born small for gestational age (SGA) (< 10th percentile) and 60,763 born 
with low birth weight (< 2500 g); 11,001 were very preterm births (< 32 gestational weeks) and 3,109 deliveries 
were stillbirths (intrauterine death > 500 g). Maternal, newborn and subgroup characteristics are specified in 
Table 1. Throughout the study period, the outcome rates of all primary and secondary outcomes stayed relatively 
constant (see Fig. 2). We did not observe a significant underlying trend in primary or secondary outcomes over 
the study period in the regression models of our main analyses.
Results of main analysis. For the two primary and two out of three secondary outcomes, i.e. preterm 
birth, SGA, low birth weight and stillbirth, any effect on level changes or slope changes following implementa-
tion of the legislation in January 2008 was not statistically significant. We observed small effects with 95% con-
fidence intervals (CIs) that include a decrease as well as an increase of the outcome rates. Results are presented 
in Table 2 (rate ratios retrieved from exponential beta coefficients) and Fig. 2. These effect estimates can be 
interpreted as illustrated through the following example: For preterm births, we observed a rate ratio of 1.0163 
(95%CI 0.9762, 1.0580) for level change. This represents an immediate relative increase of 1.63% (95%CI − 2.38, 
5.80%) in the preterm birth rate (i.e. percentage of total births), which corresponds to a predicted increase in the 
preterm birth rate from 6.95 to 7.06% from December 2007 to January 2008. The calculated rate ratio of 0.9995 
(95%CI 0.9976, 1.0013) for the slope change represents a gradual decrease of 0.05% (95%CI − 0.24, 0.13%) in the 
preterm birth rate. This corresponds, for example, to a change in the predicted monthly preterm birth rate from 
7.031% in May 2008 to a rate of 7.025% in June 2008 and represents an average of two preterm births less every 
month after implementation of the intervention.
For the secondary outcome very preterm births we did observe a rate ratio of 0.8960 (95%CI 0.8413, 0.9542) 
for level change. This represents an immediate relative decrease of very preterm births by 10.40% (95%CI − 15.87, 
− 4.58%, p = 0.0006), corresponding to a level change from a very preterm birth rate of 0.98% in December 2007 
to 0.89% in January 2008. We also observed a rate ratio of 0.9954 (95% 0.9928, 0.9982) for a slope change in very 
preterm births. This represents a decrease of 0.46% (95%CI − 0.72, − 0.18%, p = 0.0010) in the very preterm birth 
rate, corresponding to an additional relative decrease from e.g. 0.983% in July 2009 to 0.979% in August 2009, 
representing four very preterm births less each month.
Subgroup and sensitivity analyses. Consistent with the main analysis, most of the subgroup and sensi-
tivity analyses showed small effects with confidence intervals suggesting that the effect could be in either direc-
tion (see Figs. 3 and 4 and Supplementary Fig. S2-7 online). The detailed results of the sensitivity and subgroup 
analyses are shown in Supplementary Table S1 online. Active smoking during pregnancy decreased throughout 
the study period (see Supplementary figure S8 online). For 284,421 deliveries (23%) smoking status information 
was missing and therefore not included in the subgroup analysis. The mean preterm birth rate was 2.48% (95%CI 
2.25–2.70%) and the mean SGA rate 10.52% (95%CI 10.18–10.86%) higher for smokers than for non-smokers 
(see Supplementary Fig. S9 and S10 online). We did not observe a statistically significant level or slope change 
in the number of smoking mothers following implementation of the intervention (level = − 1.53, 95%CI − 6.83, 
Figure 1.  Flow chart of study population and primary and secondary outcomes.
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4.06; slope = − 0.18, 95%CI − 0.45, 0.01). We further performed post-hoc sensitivity analyses for our secondary 
outcome very preterm birth where we could replicate our findings however without reaching statistical signifi-
cance (see Supplementary Table S2 online).
Discussion
This study is the first to assess the impact of smoke-free legislation on pregnancy outcomes conducted in Ger-
many. We did not observe clear immediate (level change) or gradual (slope change) effects of the smoke-free 
legislation on preterm birth, SGA, low birth weight and stillbirth; 95%-confidence intervals surrounding effect 
estimates suggest that the effect could be in either direction. Our findings were consistent across the majority of 
sensitivity and subgroup analyses.
We observed statistically significant immediate and gradual reductions for very preterm births. We could 
replicate these findings in the sensitivity and subgroup analyses especially for smokers; however, here the effects 
were not statistically significant, probably due to a lack of power considering the much smaller population. 
Although the preterm birth and SGA rates were higher for the most deprived quintile (BIMD 5) as compared 
to the least deprived (BIMD 1), consistent with the  literature4,11, we observed no clear differential effect of the 
legislation according to SES.
Table 1.  Maternal, newborn and subgroup characteristics by outcome; the numbers represent the number 
of newborns/mothers with the respective characteristic and the percentage of the births within the outcome 
group; SES = socio-economic status, BIMD = Bavarian Index of Multiple Deprivation, ranging from least 
deprived quintile (BIMD1) to most deprived quintile (BIMD5); SGA = small for gestational age, LBW = low 
birth weight; percent values are rounded to the second decimal place.
Maternal 
characteristics















 < 20 19,045 (1.54) 1,594 (1.90) 2,544 (2.27) 1,363 (2.24) 59 (1.90) 249 (2.26)
20–24 129,279 (10.45) 9,311 (11.13) 14,940 (13.32) 7,425 (12.22) 384 (12.35) 1,299 (11.80)
25–29 329,984 (26.67) 21,916 (26.19) 30,763 (27.43) 15,714 (25.86) 745 (23.96) 2,711 (24.64)
30–34 436,317 (35.27) 27,910 (33.35) 36,667 (32.70) 19,499 (32.09) 984 (31.65) 3,486 (31.69)
35–39 258,574 (20.90) 17,695 (21.14) 21,320 (19.01) 12,784 (21.04) 714 (22.97) 2,517 (22.88)
 ≥ 40 63,793 (5.16) 5,265 (6.29) 5,909 (5.27) 3,978 (6.55) 223 (7.17) 738 (6.71)
Missing 0 0 0 0 0 1 (0.01)
Parity
0 518,743 (41.94) 38,173 (45.61) 60,078 (53.57) 30,119 (45.57) 1,304 (41.94) 4,863 (44.21)
1 408,042 (32.99) 22,734 (27.16) 30,385 (27.09) 15,620 (25.71) 909 (29.24) 2,882 (26.20)
2 185,488 (15.00) 11,873 (14.19) 12,788 (11.40) 7,938 (13.06) 489 (15.73) 1,610 (14.64)
 ≤ 3 124,691 (10.10) 10,909 (13.03) 8,890 (7.93) 7,083 (11.66) 407 (13.09) 1,645 (14.95)
Missing 28 (0.00) 2 (0.00) 2 (0.00) 3 (0.00) 0 (0.00) 1 (0.01)
Smoking status
Smokers 69,156 (5.59) 6,240 (7.46) 12,974 (11.57) 6,846 (11.27) 248 (7.98) 901 (8.19)
Non-smokers 883,415 (71.42) 57,795 (69.10) 73,264 (65.53) 39,481 (64.98) 2,061 (66.29) 7311 (66.46)
missing 284,421 (22.99) 19,656 (23.49) 25,902 (23.10) 14,434 (18.82) 800 (25.73) 2,789 (25.35)
SES according to BIMD quintiles
BIMD 1 (least 
deprived)
163,522 (13.22) 10,677 (12.76) 13,569 (12.10) 7,402 (12.18) 404 (12.99) 1,263 (11.48)
BIMD2 147,174 (11.90) 9,823 (11.74) 12,876 (11.48) 6,921 (11.39) 338 (10.87) 1,185 (10.77)
BIMD3 168,880 (13.65) 11,366 (13.58) 15,095 (13.46) 8,222 (13.53) 399 (12.83) 1,413 (12.84)
BIMD4 362,012 (29.27) 23,660 (28.27) 32,558 (29.03) 17,333 (28.53) 895 (28.79) 3,145 (28.59)
BIMD5 (most 
deprived)
314,219 (25.40) 22,318 (26.67) 30,679 (27.36) 16,647 (27.40) 853 (27.44) 3,098 (28.16)
Missing 81,185 (6.56) 5,847 (6.97) 7,556 (6.74) 4,138 (6.81) 220 (7.08) 897 (8.15)
Nationality
German 999,383 (80.79) 67,699 (80.89) 90,647 (80.83) 49,011 (80.66) 2,367 (76.13) 8,403 (76.39)
Other nationality/
missing
237,609 (19.21) 15,992 (19.11) 21,496 (19.17) 11,752 (19.34) 742 (23.87) 2,598 (23.62)
Infant characteristics
Sex
Male 634,111 (51.26) 46,290 (55.31) 57,606 (51.37) 28,863 (47.50) 1,633 (52.52) 6,037 (54.88)
Female 602,881 (48.74) 37,401 (44.69) 54,537 (48.63) 31,900 (52.50) 1,476 (47.48) 4,963 (45.11)
Missing 0 0 0 0 0 1
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The literature shows mixed effects for the impact of smoke-free legislation on pregnancy outcomes, with a 
tendency towards a protective effect. Specifically, a recent systematic review and meta-analysis of mostly inter-
rupted time series (ITS) studies performed by Faber et al.4 observed an immediate drop (level change) in preterm 
birth, low birth weight, SGA and very preterm birth, but a gradual decline (slope change) only in SGA and very 
preterm birth. The effect estimates (risk differences) reported by the included studies were rather small for the 
outcomes preterm birth, SGA and low birth weight and greater for very preterm birth. In our study we observed, 
consistent with the meta-analysis in terms of relative effect size, unclear changes in all pregnancy outcomes fol-
lowing the smoke-free legislation except for very preterm birth.
In the absence of studies assessing pregnancy outcomes in Germany, up to now, only one published study 
employed a time series design to investigate the smoke-free legislation and found a short-term immediate 
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Figure 2.  Panel figure presenting time series of pregnancy outcomes in panels (a–e); dots represent the 
monthly percentages; white = pre-intervention period, grey = post-intervention period, red line = regression line; 
SGA = small for gestational age (R version 3.5.1, https ://www.r-proje ct.org/).
Table 2.  Estimates of level and slope changes in main analysis of primary and secondary outcomes; 
SGA = small for gestational age, LBW = low birth weight; All values are rounded to the fourth decimal place.
Outcome Rate ratio (95%CI)1 level change Rate ratio (95%CI) slope change Model type
Preterm birth 1.0163 (0.9762, 1.0580) 0.9995 (0.9976, 1.0013)
Negative binomial model with autocorrela-
tion terms
SGA 1.0063 (0.9839, 1.0292) 1.0005 (0.9995, 1.0014)
Poisson model with seasonal dummies and 
autocorrelation terms
LBW 0.9861 (0.9484, 1.0254) 0.9983 (0.9966, 1.0000) Negative Binomial with seasonal dummies
Very preterm birth 0.8960 (0.8413, 0.9542), p = 0.0006 0.9954 (0.9928,0.9982), p = 0.0010
Negative binomial model with autocorrela-
tion terms
Stillbirth 0.9583 (0.8165,1.1247) 1.0004 (0.9936, 1.0073) Poisson model
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effects of the legislation on smoking behaviour using German socio-economic panel (SOEP) data. It found no 
impact of the legislation in the general population but only for those frequenting bars and restaurants more 
 often12.
A previous study conducted in  Canada13 identified several factors, apart from methodological differences, 
that may explain the heterogeneous findings across studies assessing the effect of smoke-free legislation on 
pregnancy outcomes, namely: (i) different policy environments in terms of smoking prevalence and smoking 
norms, (ii) the presence of existing legislation prior to the smoke-free legislation under investigation, and (iii) 
differences in policy implementation and enforcement. These factors may contribute to understanding why we 
did not observe a clearer effect related to the Bavarian smoke-free legislation.
With regards to different policy environments, the smoking prevalence in other countries was similar to the 
prevalence in Germany, ranging from 18 to 27% among the female  population14–20. However, Germany, with a 
prevalence of 27% in 2008–2011 lies at the upper end of this  range21 and Germany’s efforts in tobacco control 
have been poor compared to other  countries22–24. According to the Tobacco Control Ranking Scale  201925, 
Germany occupies the last rank for successful implementation of tobacco control among 36 mostly European 
countries. For example, Germany currently is the only EU country, which still allows tobacco advertising on 
 billboards1. Tobacco smoking is a well-established risk factor for fetal growth restriction and preterm birth. 
Indeed, we found large differences between smoking and non-smoking mothers regarding rates of preterm 
birth and especially SGA. However, we did not observe any drop or gradual decrease of preterm birth or SGA 
rates in either subgroup following the implementation of the smoke-free legislation. Furthermore, we did not 
observe changes in smoking rates related to the implementation of the legislation as assumed in our logic model 
and shown in other  studies14,17,18. However, caution is merited, as a 5.9% smoking prevalence in our data is very 
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Figure 3.  Rate ratios with 95%CIs for level and slope changes of preterm birth, sensitivity (●) and subgroup 
(▲) analyses (R version 3.5.1, https ://www.r-proje ct.org/).
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more health-conscious behaviour among pregnant women, who, prior to implementation of the smoke-free 
legislation, already avoided exposure to second-hand smoke.
Considering pre-existing legislation, as laid out in our logic model, the smoke-free legislation is not the only 
factor influencing pregnancy outcomes, and we did identify co-interventions and existing legislation prior to 
implementation of the legislation under investigation that may have subdued a more prevalent effect.
Finally, regarding the role of policy implementation and enforcement, recent studies have shown that the 
health impact is larger when the smoke-free legislation is more  comprehensive4,26. While Bavaria has one of 
the strictest smoke-free legislations within Germany, the legislation lacked supporting interventions, such as 
an accompanying media campaign or tax increase. Studies in Spain, England and Scotland, where improve-
ments in pregnancy outcomes associated with legislation were observed, also found high compliance with the 
 legislation17,18,27. While we do not have data in Bavaria regarding actual enforcement or compliance, it is pos-
sible that the unclear effects could be explained by a lack of enforcement or compliance considering Germany’s 
lacking efforts in tobacco  control12,22,24.
The ITS study design is prone to certain methodological limitations. The lack of randomization and 
thus potential confounding make it difficult to definitely attribute causality to the intervention-outcome 
 relationship5,28. Beyond this design-inherent limitation, the use of rigorous a priori methods is important.
We used a high quality, large dataset and followed the steps outlined in the tutorial developed by Lopez Bernal 
et al.29 to account for common methodological and conceptual flaws in assessing population level interven-
tions with time series  designs30. In particular, we took a complex systems approach and used a logic model to 
conceptualize our study and identified co-interventions and other risk factors prior to conducting our  study31. 
We registered a detailed study protocol, in which we defined an impact model, the main statistical analysis, as 
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Figure 4.  Rate ratios with 95%CIs for level and slope changes of small for gestational age (SGA), sensitivity (●) 
and subgroup (▲) analyses (R version 3.5.1, https ://www.r-proje ct.org/).
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including the full range of data from 2000 to 2016, we would have come to different conclusions. However, in 
such a model the pre-intervention slope (and therefore level and slope change) was defined primarily by a major 
breakpoint in 2004 caused by several co-interventions in this year. This emphasizes the importance of choosing 
an appropriate impact model, as described by Lopez Bernal et al.32.
Our choice of the correct impact model, however, was also associated with several uncertainties. Many aspects 
of biological processes of pregnancy and especially the exact window of susceptibility of pregnancy to smoking 
are insufficiently  understood33,34. Also, the interrupted implementation of the legislation in Bavaria from 2008 
to 2010 makes it difficult to identify the exact time at which we can expect to see an effect. Some studies have 
investigated an immediate  onset18,19, or even an anticipatory intervention time  point17 whereas others have used 
an intervention time point nine months after the actual implementation of the  intervention13. A study which 
investigated the smoke-free legislation in the different cantons of Switzerland, found that the more time a mother 
spent under the smoke-free legislation the fewer were the risks for preterm birth and early-term  births20.
A further design-inherent weakness of the single-arm ITS study design is the lack of a concomitant, geo-
graphical control  group35. Indeed, a recent study has shown the limitations of single group ITS studies assessing 
the impact of smoke-free legislation on mortality in Spain where initial protective intervention effects from a 
single group ITS study were not confirmed after the addition of a comparable geographical control  site36. Despite 
careful preparation and consideration, we may have failed to identify important confounders or co-interventions, 
considering the complexity of the intervention as well as of the system in which it was implemented. Additionally, 
little concrete guidance on choice of statistical model exists, and determining the ‘best-fit’ model among a range 
of alternatives remains at least partially arbitrary. Gasparrini et al.37 already concluded that the model specifica-
tions, among other factors, have a strong impact on the effect estimate when assessing smoke-free legislation on 
acute myocardial infarction. We aimed, however, to define statistical parameters a priori, where possible, and to 
comprehensively report modelling choices by publishing our code alongside the manuscript.
Methods
We applied an ITS study design to assess the association between implementation of the smoke-free legislation 
and pregnancy outcomes using monthly data from all births in Bavaria between 2005 and 2016. The ITS study 
design is considered to be one of the best alternatives to assess intervention effectiveness of population-level 
interventions where randomization is considered  infeasible29,38. It is increasingly used in the field of healthcare 
and public  health39,40. This study design usually draws on routine data collected over time to identify any under-
lying time trends, and can thereby observe changes after the implementation of an intervention compared to 
a counterfactual scenario (i.e. a hypothetical scenario in which the intervention was not  implemented41). We 
pre-specified the study methods including the main impact model, main analysis, and subgroup and sensitivity 
analyses in a study protocol (available at www.drks.de, study ID: DRKS00014805).
Data source. We included aggregated data from a high-quality routine dataset of maternal and neonatal 
health indicators, collected and managed by the Bavarian Institute for Quality Assurance in hospital care (BAQ). 
This dataset contains all Bavarian in-hospital births, which constitute about 99% of all births in  Bavaria42. It 
provides extensive information retrieved from all hospitals in Bavaria regarding maternal and neonatal demo-
graphic and health-related characteristics, clinical management, and pregnancy complications. The data are sub-
jected to a series of formal and contextual plausibility  checks43.
Outcomes. Our primary outcomes included preterm birth (< 37 gestational weeks), and SGA (< the 10th 
percentile, adjusted for gestational age and sex based on Voigt et al.44), both measured as the percentage of these 
outcomes among all births that occurred during a given month. Secondary outcomes included monthly per-
centages of low birth weight (< 2500 g), very preterm birth (< 32 gestational weeks), and stillbirth (intrauterine 
death > 500 g).
Inclusion and exclusion criteria. We included all live and non-live singleton births from 24 until 42 com-
pleted weeks of gestation that occurred between January 2005 and December 2016. We excluded pregnancies 
with multiple births due to their increased risk of preterm birth, low birth weight and other pregnancy complica-
tions. We also excluded pregnancies with unknown gestational length and children with unknown birth weight.
Logic model. We developed a logic model that describes how the intervention and other factors influence 
pregnancy outcomes (see Fig.  5) to conceptualise the study and decide on the impact model and statistical 
analysis. The logic model, derived from literature searches, within-team discussions and expert consultations, 
provides a structure to help authors address complexity and thus better understand the interactions between the 
intervention, its implementation and multiple outcomes among a population and  context45,46.
We identified several co-interventions (i.e. other interventions, measures or policies that occur during the 
same time period) and other risk factors influencing pregnancy outcomes over the study period, which we 
describe in detail in our study protocol.
Impact model. The 16 German federal states are responsible for the implementation of the national law 
for the protection of non-smokers, and individual state legislation varies in strength (e.g. partial smoke-free 
laws), as well as in timing of implementation (ranging from August 2007 to July 2008). Bavaria implemented the 
smoke-free legislation on 1 January 2008. Thereafter, smoking was prohibited in all public buildings and institu-
tions, such as universities, hospitals, retirement and nursing homes, and restaurants and  bars47. Due to political 
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arguments, however, the Bavarian legislation was loosened on 1 August 2009, and smoking was permitted again 
in a subset of restaurants, e.g. in restaurants larger than 75  m2 mainly serving drinks. Following a referendum, 
which allowed Bavarian citizens to vote directly for or against more restrictive smoke-free legislation, the leg-
islation was tightened again on 1 August 2010. This iteration additionally banned smoking in beer and event 
 tents48,49, making the Bavarian smoke-free legislation one of the strictest in  Germany48. Violations of smoke-free 
legislation for smokers as well as event organisers include fines between 5 and 1,000 Euros, but information on 
enforcement and compliance is lacking.
We hypothesized that the effects of the smoke-free legislation may be detected as an immediate drop (level 
change) and gradual decline (slope change) in pregnancy outcomes at the first introduction of the smoke-free 
legislation on 1 January 2008. The changes could be the result of an immediate reduction in maternal exposure 
to SHS, and/or an immediate reduction in active maternal smoking (in public places and potentially elsewhere). 
They could also be impacted by longer-term influences on sociocultural norms, affecting smoking behaviours 
in different  settings50–52.
Originally, we planned to use data from 2000 to 2016 with equal time periods pre- and post-intervention. 
Upon visual inspection of the data we identified, however, a series of pronounced changes in outcome rates in the 
year 2004, during the pre-intervention period, that we were not able to sufficiently account for through adjust-
ments in the analysis. These changes were potentially triggered by the smoking ban at work in August  20047, a 
major cigarette price increase in September  200453, as well as a documentation change initiated in January 2004. 
Therefore, we shortened the pre-intervention time period, using data from 2005 to 2016. The main impact model 
is therefore based on a pre-intervention period from January 2005 to 31 December 2007 and a post-intervention 
period from 1 January 2008 until 31 December 2016. We report, however, additional sensitivity analyses using 
data from 2000 to 2016.
Statistical analyses. We performed a segmented regression analysis using a generalized linear model with 
log-link for all  analyses29,36. As the analysed monthly data were not independent from one another, we adjusted 
for seasonality through the inclusion of monthly dummy variables and/or for autocorrelation through the inclu-
sion of auto-regressive structures in the model. We performed goodness-of-fit tests to decide whether to use 
a Poisson or a more flexible Negative Binomial model. We scrutinized auto-correlation function (ACF) and 
partial auto-correlation function (PACF) plots visually and compared Akaike’s information criteria (AIC) to see 
whether the model performed better after adjustment for seasonality and/or remaining autocorrelation.
Figure 5.  Logic model of the Bavarian smoke-free legislation.
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The final models were generalized linear models (Poisson or Negative Binomial depending on the outcome) 
including seasonal dummy variables and/or a random effect term comprising the appropriate autoregressive 
terms. As we were dealing with count data, we were using the population as an offset variable in order to trans-
form back to rates. The main statistical formula is depicted below:
where t is the log of monthly outcome rates measured at each month of observation t, and timet is a continuous 
variable modelling each month since January 2005 (1,2,3…–145), levelj a binary predictor for the legislation, 
which is modelled as 0 in the pre-legislation time period (January 2005–December 2007) and 1 in the post-
legislation period (January 2008–December 2016). slopejt is an interaction term of the legislation with time. In 
this model β0 represents the baseline outcome rate, β1 the change in outcome rate per one unit increase in time 
(month) (i.e. the underlying pre-legislation trend), β2 the level change in outcome following the legislation and 
β3 the slope change in outcome following the legislation.
We performed data management with SAS software version 9.454, and the analyses using  R55. The complete 
R code for the main statistical analysis is available in the Supplementary Information online.
Subgroup and sensitivity analyses. We specified a series of sensitivity and subgroup analyses a priori 
for the primary outcomes preterm birth and SGA (see Table 3). We further performed post-hoc sensitivity analy-
ses for the secondary outcome very preterm birth to verify the findings in the main analysis.
Ethics statement. As we use anonymous, routinely collected data, separate ethics approval was not required 
for this study, as confirmed by a waiver obtained from the ethics commission of the LMU Munich. The Bavarian 
Institute for Quality Assurance in hospital care (BAQ) approved the use of the data.
Data availability
The data that support the findings of this study are available from the Bavarian Institute for Quality Assurance 
in hospital care (BAQ) but restrictions apply to the availability of these data, which were used under license for 
the current study, and so are not publicly available. Data are however available from the authors upon reasonable 
request and with permission of BAQ.
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Table 3.  Sensitivity and subgroup analysis descriptions.
Sensitivity analyses
Varying time lags
We tested different intervention time points with three and six month time lags to assess if our assumption that smoking can affect pregnancy 
outcomes at any stage during pregnancy was correct
Excluding transition period
We excluded the data from 1 January 2008 (when the first smoking ban was implemented) until 1 August 2010 (when the smoking ban was 
reinstated) to compare the time period prior to the first ban to the period after implementation of the tightened ban
Including a longer pre-intervention period (2000–2016) (post-hoc)
We analysed the originally planned impact model with a study period from 2000 to 2016
Excluding induced births
We analysed spontaneous preterm births only, as smoking is associated with the spontaneous preterm onset of labour due to the inflamma-
tory responses it triggers and higher risk of intrauterine uterine infections (Goldenberg, Culhane, Iams, & Romero, 2008). We could thereby 
also account for the potential effects of the introduction of gestational diabetes screening in  201156, which is associated with induced preterm 
births
Excluding preterm infants at the border of viability
We excluded infants born between 24 and 27 completed gestational weeks and only assessed infants born between 28 and 36 gestational 
weeks to rule out any effect of changes in data documentation practices after implementation of the guidelines on premature infants on the 
border of  viability57
Including only mothers of German nationality
We excluded all mothers born outside of Germany to rule out any effect of the recent increase in refugees starting in 2014 in Germany
Subgroup analyses
Smoking status
We tested if outcomes rates differed between actively smoking and non-smoking mothers (see Mackay et al.17). Smoking, as reported by the 
mother, is recorded when registering in hospital. We further assessed post-hoc whether the smoking rates differed after implementation of 
the smoke-free legislation
Socio-economic status (SES)
We wanted to assess the impact of tobacco control policies on marginalised populations and assessed whether the legislation had a different 
effect on different socio-economic groups. Individual-level SES data were not available, and we thus used the area-level Bavarian Index of 
Multiple Deprivation (BIMD) as a proxy for individual  SES58,59. We therefore assigned each mother a BIMD quintile based on the postal code 
of her residential address. We then performed subgroup analyses according to each BIMD quintile
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Table S1 Estimates of changes in level and slope in subgroup and sensitivity analyses of primary 
outcomes. 




Model type (and R package 
used) 
Sensitivity analyses 
3-month lag after legislation implementation 
Preterm birth 1.0177 
(0.9849,1.0516) 
0.9991 (0.9978,1.0004) Seasonally adjusted 




1.0006 (0.9998, 1.0014) Poisson model (glarma) with 
seasonal dummies and 
autocorrelation terms 
6-month lag after legislation implementation 





Negative Binomial model 
(glm) 
SGA 1.0097 (0.9930, 
1.0267) 
1.0005 (1.0000, 1.0010) Poisson model (glarma) with 
seasonal dummies and 
autocorrelation terms 
Excluding data of a 2-year transition period after legislation implementation 
Preterm birth 0.9758 (0.9384, 
1.0147) 





1.0006 (0.9999, 1.0013) Poisson model (glarma) with 
autocorrelation terms 
Including a longer pre-intervention period (2000-2016) (post-hoc) 
Preterm birth 0.9879 (0.9546, 
1.0223) 
0.9984 (0.9978, 0.9989), 
p=0.0000 
Negative Binomial model 





1.0008 (1.0006, 1.0010), 
p=0.0000 
Poisson model (glarma) with 
seasonal dummies & 
autocorrelation terms 
Excluding induced births 
Preterm birth 1.0141 (0.9697, 
1.0605) 
0.9995 (0.9976, 1.0014) Negative binomial model 




1.0001 (0.9992,1.0010) Poisson model (glarma) with 
autocorrelation terms 







Negative binomial model 
(glarma) with 
autocorrelation terms 
SGA 1.0104 (0.9916, 
1.0296) 
1.0007 (1.0000,1.0014) Poisson model (glarma) with 
autocorrelation terms 
Including only mothers of German nationality 
Preterm birth 1.0053 (0.9642, 
1.0482) 
0.9985 (0.9965, 1.0004) Negative binomial model 
(glarma) with 
autocorrelation terms 
SGA 1.0179 (0.9879, 
1.0489) 






Smoking status  


























1.0003 (0.9992, 1.0014) 
Poisson model (glarma) with 
autocorrelation terms 
Socio-economic status – Preterm birth  




1.0006 (0.9990, 1.0023) Poisson model (glarma) with 
autocorrelation terms 
BIMD quintile 2 1.0090 (0.9314, 
1.0932) 
0.9951 (0.9916, 0.9986), 
p=0.0061 
Poisson model (glarma) with 
autocorrelation terms 
BIMD quintile 3 0.9982 (0.9186, 
1.0847) 
0.9982 (0.9947, 1.0018) Unadjusted Poisson model 
BIMD quintile 4 0.9826 (0.9256, 
1.0430) 
0.9973 (0.9946, 1.0000), 
p=0.04 
Poisson model (glarma) with 
autocorrelation term 




1.0006 (0.9971, 1.0041) Negative binomial model 
(glarma) with 
autocorrelation terms 
Socio-economic status – SGA 




1.0017 (0.9980, 1.0054) Poisson model (glarma) with 
autocorrelation terms 
BIMD quintile 2 1.0556 (0.9731, 
1.1450) 
1.0019 (0.9985, 1.0055) Unadjusted Poisson model 
BIMD quintile 3 0.9403 (0.8743, 
1.0114) 
0.9966 (0.9935, 0.9988), 
p=0.03 
Poisson model (glarma) with 
autocorrelation terms 
BIMD quintile 4 1.0010 (0.9628, 
1.0407) 
1.0001 (0.9985, 1.0017) Poisson model (glarma) with 
autocorrelation terms 




1.0009 (0.9988, 1.0032) Unadjusted Poisson model 
 
Table S2 Post-hoc sensitivity analyses very preterm birth 
Sensitivity analyses Exponential level 
coefficient (95%CI)* 
Exponential slope 
coefficient  (95%CI) 
Model type (and R package 
used) 
3 month lag 0.9077 (0.8291, 
0.9938), p= 0.0364 
0.9962 (0.9922, 
1.0002) 
Negative binomial model 
(glarma) with autocorrelation 
terms 





Negative binomial model 
(glarma) with autocorrelation 
terms 
2-year transition period 0.9745 (0.9357, 
1.0149) 
0.9985 (0.9961,1.0001) Negative binomial model 
(glarma) with autocorrelation 
terms 






Negative binomial model 
(glarma) with autocorrelation 
terms 
Excluding induced births 0.8667 (0.7297, 
1.0308) 
0.9954 (0.9880,1.0028) Negative binomial model 
(GLM) with seasonal 
adjustment 
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0.9957 (0.9906,1.0007) Negative binomial model 
(glarma) with autocorrelation 
terms 
Smokers 0.8161 (0.6318, 
1.0540) 




0.9956 (0.9908,1.0004) Unadjusted negative binomial 
model (glm) 
BIMD 1 0.9365 
(0.7316,1.1987) 
0.9963 (0.9856,1.0071) Unadjusted Poisson model 
BIMD 2 1.0361 (0.7958,1.349) 0.9938 (0.9822,1.0055) Unadjusted Poisson model 
BIMD 3 1.0595 
(0.8311,1.3508) 
1.0037 (0.9934,1.0141) Unadjusted Poisson model 
BIMD 4 0.8845 
(0.7690,1.0174) 
0.9935 (0.8637,1.1473) Negative binomial model 
(glarma) with autocorrelation 
terms 
BIMD 5 0.8992 
(0.7869,1.0275) 
0.9979 (0.9909,1.0049) Negative binomial model 




R Script of main analysis 
 





source("/Users/likTestsNEW.R") #in the glarma package this was necessary to be able to use 
the package properly 
source("/Users/summary.glarmaNEW.R") #sources kindly provided by William Duinsmuir 
 
#retrieve data 




smoke$year <- smoke$YEAR 
smoke$YEAR <- NULL 
smoke$month <- smoke$MONTH 
smoke$MONTH <- NULL 
smoke$pb <- smoke$PB 
smoke$PB <- NULL 
smoke$vpb <- smoke$VPB 
smoke$VPB <- NULL 
smoke$sga <- smoke$SGA 
smoke$SGA <- NULL 
smoke$lbw <- smoke$LBW 
smoke$LBW <- NULL 
smoke$still <- smoke$STILL 
smoke$STILL <- NULL 
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smoke$n <- smoke$N 
smoke$N <- NULL 
smoke$t <- smoke$T 
smoke$T <- NULL 
 
#We delete the data smaller 2005 and bigger than 2016 
smoke <- smoke %>% filter(year >=2005 & year != 2017)  
 
#We set time variabe t at new dataset start 
smoke$t <- 1:nrow(smoke) 
 
############## 
#create time variables 
################ 
cp <- 37 #set intervention time point on 1 January 2008 
smoke$level <- ifelse(smoke$t<cp, 0, 1) 
 
smoke$slope <- c(rep(0, cp-1), 1:(145-cp)) 
 
 
#plot  whole time series 
# start the plot, excluding the points and the x-axis 
plot(smoke$pb,type="n",ylim=c(0.05,0.09),xlab="Year", ylab="Preterm birth rate", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
abline(v=37,lty=2)  
# plot the observed rate for intervention period 
points(smoke$pb,cex=0.7, col="red")  #oder mit points 
lines(smoke$pb,cex=0.7, col="red") 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 





plot(smoke$pbn,type="n",ylim=c(450,700),xlab="Year", ylab="Preterm birth rate", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
abline(v=37,lty=2)  
# plot the observed rate for intervention period 
points(smoke$pbn,cex=0.7)  #oder mit points 
lines(smoke$pbn,cex=0.7) 




# add a title 
title("Preterm rate, 2005-2016") 
 
#create offset for model 
smoke$pbn <- smoke$pb * smoke$n 
smoke$logn <- log(smoke$n) 
head(smoke) 
 
#first try of glm model 




# goodness of fit test: if test is significant, model fit is not good 
1 - pchisq(summary(model1)$deviance,  
           summary(model1)$df.residual)  
 
 
#negative binomial model 
model2 <- glm.nb(pbn ~ offset(logn) + t + level + slope, data=smoke, link=log)  
summary(model2)  
 
1 - pchisq(summary(model2)$deviance,  




acf(residuals(model2),type='partial') #looks like months/seasonality play more of a role 
 
#plot residuals 
plot(smoke$t, residuals(model2), type='o', pch=16) 
 
#adjust with monthly dummies 
smoke$jan <- ifelse(smoke$month==1, 1,0) 
smoke$feb <- ifelse(smoke$month==2, 1,0) 
smoke$mar <- ifelse(smoke$month==3, 1,0) 
smoke$apr <- ifelse(smoke$month==4, 1,0) 
smoke$may <- ifelse(smoke$month==5, 1,0) 
smoke$jun <- ifelse(smoke$month==6, 1,0) 
smoke$jul <- ifelse(smoke$month==7, 1,0) 
smoke$aug <- ifelse(smoke$month==8, 1,0) 
smoke$sep <- ifelse(smoke$month==9, 1,0) 
smoke$oct <- ifelse(smoke$month==10, 1,0) 
smoke$nov <- ifelse(smoke$month==11, 1,0) 
smoke$dec <- ifelse(smoke$month==12, 1,0) 
 
 
model3 <- glm.nb(pbn ~ offset(logn) + t + level + slope + jan + feb + mar + apr + may +  
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plot(smoke$t, residuals(model3), type='o', pch=16) 
#goodness of fit test 
1 - pchisq(summary(model3)$deviance,  
           summary(model3)$df.residual) #looks good 
 
 
#look for remaining autocorrelation 
par(mfrow=c(1, 2)) 
acf(residuals(model3))  




source("/Users/stephie/LRZ Sync+Share/ITS PhD/likTestsNEW.R") 
source("/Users/stephie/LRZ Sync+Share/ITS PhD/summary.glarmaNEW.R") 
 
predictors <- cbind(intercept <-(rep(1, dim(smoke)[1])),  
                    slope <-smoke$slope, level <- smoke$level, t <-smoke$t) 
 
colnames(predictors) <- c("intercept", "slope", "level", "t") 
 
model5 <- glarma(smoke$pbn, predictors, offset = smoke$logn, type = "NegBin",  






#plot regression line 
dev.off() 
# start the plot, excluding the points and the x-axis 
plot(smoke$pb,type="n",ylim=c(0.05,0.09),xlab="Year", ylab="Preterm birth percentage", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
rect(37,0.05,145,0.09,col=grey(0.9),border=F)  
# plot the observed rate for intervention period 
points(smoke$pb,cex=0.7) 
lines(smoke$pb,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 
title("a. Preterm birth") 
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#plot regression line with glarma model 
coef(model5) 
predict <- exp(smoke$logn + coef(model5)$beta[1]  
               + smoke$t*coef(model5)$beta[4]   
               + smoke$level*coef(model5)$beta[3]   









# start the plot, excluding the points and the x-axis 
plot(smoke$sga,type="n",ylim=c(0.08,0.11),xlab="Year", ylab="SGA rate", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
abline(v=37,lty=2)  
# plot the observed rate for intervention period 
points(smoke$sga,cex=0.7, col="red")  #oder mit points 
lines(smoke$sga,cex=0.7, col="red") 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 
title("SGA rate, 2005-2016") 
 
 
#create offset for model 
smoke$sgan <- smoke$sga * smoke$n 
head(smoke) 




# If test is significant, model fit is not good 
1 - pchisq(summary(model1)$deviance,  




acf(residuals(model1),type='partial') #again seasonality?  
 
#plot residuals 
plot(smoke$t, residuals(model1), type='o', pch=16) 
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#model with monthly dummies 
model2 <- glm(sgan ~ offset(logn) + t + level + slope + jan + feb + mar + apr + may  
              + jun + jul + aug  + oct + nov + dec,  









predictors <- cbind(intercept <-(rep(1, dim(smoke)[1])),  
                    slope <-smoke$slope, level <- smoke$level, t <-smoke$t, 
                    jan <- smoke$jan, feb <- smoke$feb,mar <- smoke$mar, 
                    apr <- smoke$apr, may <- smoke$may, jun <- smoke$jun,  
                    jul <- smoke$jul, aug <- smoke$aug, oct <- smoke$oct,  
                    nov <- smoke$nov, dec <- smoke$dec) 
 
colnames(predictors) <- c("intercept", "slope", "level", "t", "jan", "feb", "mar", 
                          "apr", "may", "jun", "jul", "aug", "oct", "nov", "dec") 
 
 
model4 <- glarma(smoke$sgan, predictors, offset = smoke$logn, type = "Poi") #seasonal 











#try glarma with autocorrelation 
model4_10 <- glarma(smoke$sgan, predictors, offset = smoke$logn, type = "Poi", phiLags = 




acf(residuals(model4_10),type='partial') #looks ok with monthly dummies and AR structure 
 
#plot regression line 
plot(smoke$sga,type="n",ylim=c(0.08,0.11),xlab="Year", ylab="SGA percentage", 
     bty="l",xaxt="n") 




# plot the observed rate for intervention period 
points(smoke$sga,cex=0.7) 
lines(smoke$sga,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 
title("b. SGA") 
 
#print regression line 
coef(model4_10) 
 
predict <- exp(smoke$logn + coef(model4_10)$beta[1]  
               + smoke$t*coef(model4_10)$beta[4]   
               + smoke$level*coef(model4_10)$beta[3]   









plot(smoke$lbw,type="n",ylim=c(0.04,0.07),xlab="Year", ylab="LBW percentage", 
     bty="l",xaxt="n") 
# shade the post intervention period grey 
rect(37,0.04,145,0.07,col=grey(0.9),border=F)  
# plot the observed rate for intervention period 
points(smoke$lbw,cex=0.7) 
lines(smoke$lbw,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 





#create offset for model 








# goodness of fit test 
1 - pchisq(summary(model2)$deviance,  






#try with seasonal adjustment 
model3 <- glm.nb(lbwn ~ offset(logn) + t + level + slope + jan + feb + mar + apr + may  






acf(residuals(model3),type='partial') #looks good with seasonal adjustment 
 
#plot regression line 
#pred <- predict(model3,type="response") 
plot(smoke$lbw,type="n",ylim=c(0.04,0.07),xlab="Year", ylab="LBW rate", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
#abline(v=37,lty=2)  
# shade the post intervention period grey 
rect(37,0.04,145,0.07,col=grey(0.9),border=F) 
# plot the observed rate for intervention period 
points(smoke$lbw,cex=0.7) 
lines(smoke$lbw,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 





#without seasonality visible: 
 
newdata  <- smoke 
head(newdata) 
newdata[(14:25)] <- 0 
#plot new data without seasonality 
pred3 <- predict(model3,newdata=newdata) 
coef(model3) 
mean_months <- mean(coef(model3)[5:15]) 
 









#plot stillbirth rate 
plot(smoke$still,type="n",ylim=c(0.001,0.005),xlab="Year", ylab="stilbirth percentage", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
#abline(v=37,lty=2)  
rect(37,0.001,145,0.005,col=grey(0.9),border=F) 
# plot the observed rate for intervention period 
points(smoke$still,cex=0.7) 
lines(smoke$still,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 




#create offset for model 
smoke$stilln <- smoke$still * smoke$n 
head(smoke) 




# If test is significant, model fit is not good 
1 - pchisq(summary(model1)$deviance,  





acf(residuals(model1),type='partial') #looks already good 
 
#plot regression line 
 
plot(smoke$still,type="n",ylim=c(0.001,0.005),xlab="Year", ylab="stillbirth rate", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
#abline(v=37,lty=2)  
rect(37,0.001,145,0.006,col=grey(0.9),border=F) 




#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 
title("Stillbirth rate, 2005-2016") 
 
#plot regression line 








plot(smoke$vpb,type="n",ylim=c(0.005,0.014),xlab="Year", ylab="Very PB percentage", 
     bty="l",xaxt="n") 
# Add line indicating the policy changes 
#abline(v=37,lty=2)  
rect(37,0.005,145,0.014,col=grey(0.9),border=F) 
# plot the observed rate for intervention period 
points(smoke$vpb,cex=0.7)  #oder mit points 
lines(smoke$vpb,cex=0.7) 
#specify the x-axis (i.e. time units) 
axis(1,at=0:12*12,labels=F) 
axis(1,at=0:12*12,tick=F,labels=2005:2017) 
# add a title 
title("e. very preterm birth") 
 




model2 <- glm.nb(vpbn ~ offset(logn) + t + level + slope, data=smoke, link=log)  
summary(model2)  
 
1 - pchisq(summary(model2)$deviance,  




acf(residuals(model2),type='partial') #autocorrelation still present 
 
#model with autocorrelation adjustment 
predictors <- cbind(intercept <-(rep(1, dim(smoke)[1])),  
                    slope <-smoke$slope, level <- smoke$level, t <-smoke$t) 
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colnames(predictors) <- c("intercept", "slope", "level", "t") 
 






acf(residuals(model4))   
acf(residuals(model4),type='partial')  
 
#plot regression line 
coef(model4) 
 
predict <- exp(smoke$logn + coef(model4)$beta[1]  
               + smoke$t*coef(model4)$beta[4]   
               + smoke$level*coef(model4)$beta[3]   
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In this research note, we assess the influence that different methods to analyse controlled 23 
before-after (CBA) studies have on the size of the effect estimate and the associated precision 24 
using a worked example.  25 
Results: 26 
Methods commonly applied in CBA studies can lead to misleading conclusions if the statistical 27 
analysis fails to fully exploit the structure of the collected data, or to take clustering into 28 
account. With increasing use of CBA studies, researchers should make best use of difference-29 
in-differences methods and appropriately adjust for clustering. Systematic reviewers may 30 
need to re-analyse incorrectly or insufficiently analysed CBA studies. 31 
 32 
 33 
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 37 
Introduction 38 
The controlled before-after (CBA) study was found, along with the interrupted time series (ITS) 39 
study, to be the nonrandomised study design most often included in Cochrane reviews (1, 2). 40 
The CBA study uses pre- and post-intervention measurements in an intervention and a control 41 
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group to assess whether an effect of an intervention is observed in the intervention group 42 
relative to the control group (3). CBA studies often use a clustered design where sites, such as 43 
healthcare centres, schools or regions within a country, are allocated to an intervention or a 44 
control group (4). They are commonly used in health services and public health research, 45 
where randomisation may be unfeasible, unethical or simply difficult to implement (5).  46 
In a recent study assessing the methodological characteristics of CBA and ITS studies included 47 
in Cochrane reviews, we found that many CBA studies applied suboptimal or even 48 
inappropriate analysis methods (2). This may lead to distorted conclusions about the 49 
intervention effect. In randomised controlled trials (RCTs), researchers have long focused on 50 
analysis methods (6). Bland and Altman (7), for example, described in detail how within group 51 
comparisons in RCTs may lead to highly misleading interpretations. In CBA studies where 52 
randomisation is lacking, it is all the more important to understand the implications of 53 
different analysis methods, both with respect to the findings of individual studies as well as 54 
with respect to the conclusions of systematic reviews drawing on such studies. 55 
We assessed the influence that different analysis methods commonly applied in CBA studies 56 
have on the size of the effect estimate and the associated precision using a worked example. 57 
Main text 58 
Methods 59 
We re-analysed a previously conducted CBA study that assessed the impacts of the so-called 60 
community-based newborn care package (CBNCP) in Nepal (8). The CBNCP, which comprises 61 
seven community- and home-based interventions, was implemented by the Ministry of Health 62 
in ten out of 75 districts in Nepal in 2009 and 2010 to tackle major causes of neonatal 63 
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mortality. The study examined the impacts of this large-scale government programme on 64 
women’s behaviours influencing neonatal health in ten intervention and ten control districts, 65 
using data from the Nepal Demographic and Health Survey (DHS) among other sources (9). 66 
The ten control districts were chosen using propensity score matching (8). We used the DHS 67 
data analysed in this study for our worked example, focusing on one of the selected 68 
behaviours among women, i.e. recommended antenatal care seeking.  69 
 70 
The controlled before-after study design 71 
The CBA study is broadly described as a study design in which observations are made before 72 
and after the implementation of an intervention, both in a group that receives the 73 
intervention and in a control group that does not. Figure 1 is a simplified illustration of the 74 
design showing the intervention group (grey square) and the control group (black dot). They 75 
may represent one, or a mean of several measurements taken over time before and after the 76 
intervention, respectively. In the following we introduce commonly used analysis methods 77 
identified in a previous study (2). Figure 2 comprises panels a-f representing the different 78 





Figure 1 Simplified controlled before-after study design, adapted from Grimshaw, Campbell 82 
(10) 83 
 84 
Analysis A: Comparison of post-intervention means between intervention and control 85 
groups 86 
The study may utilize only post-intervention data in the analysis, i.e. the post-intervention 87 
mean in the intervention group is compared with the post-intervention mean of the control 88 
group (see Fig 2a). This type of analysis has already been criticized for RCTs (7). In CBA studies, 89 
where balanced baseline groups are much more difficult to obtain if at all possible, ignoring 90 









Analysis B: Comparison of pre- and post-intervention means of the intervention group only 96 
The study, despite measuring the outcome in a control group, may not include these 97 
measurements in a statistical analysis but may calculate the difference between pre- and post- 98 
measurements in the intervention group only (see Fig 2b). Changes in the outcome, however, 99 
might also reflect general developments in the population, independent from the intervention 100 
(e.g. economic trends, implementation of other large-scale programs, new regulations, etc.). 101 
By focusing only on the pre-post differences in the intervention group, the effect of the 102 
intervention will not be isolated, providing biased effect estimates. 103 
 104 
Analysis C: Separate comparison of pre-post differences in intervention and control group 105 
The study may analyse within-group differences but not compare the differences between the 106 
groups statistically (see Fig 2c). Again, the effect of treatment will not be isolated from the 107 
effect of other potential influences, resulting in potentially biased estimates. 108 
 109 
Analysis D: Difference-in-differences analysis, adjusting for clustering 110 
The difference-in-differences (DiD) analysis takes into account all measurements in both 111 
groups and estimates the differences between the within-group differences. It therefore 112 
accounts for time-dependent trends in the outcome unrelated to the intervention, assuming 113 
parallel trends in the groups. The estimated effect is calculated by (I2−I1) - (C2−C1) (11) (see 114 
Fig 2d). In studies where data are aggregated from different sites or groups, it is important 115 





Analysis E: Difference-in-differences analysis, not adjusting for clustering  119 
In CBA studies there may be two (e.g. individual, family) (see Fig 2e) or more levels (e.g. 120 
individual, family, community) (see Fig 2f) that should be accounted for in the analysis. This is 121 
called clustering (in the case of two levels) or nesting (if three or more levels are present) (5). 122 
If the analysis simply lumps the means (and standard deviations) of each of the sites together 123 
into a single site, ignoring the individual-level data, the study will make inefficient use of the 124 
data and the standard error will be much larger than needed. On the other hand, if the analysis 125 
aggregates the data of all sites together and then treats it on an individual level, it will create 126 
a serious unit of analysis error: the standard errors will be much smaller than they actually are 127 
(12). 128 
 129 
Application to worked example 130 
For our worked example we calculated the proportion of women adhering to recommended 131 
antenatal care seeking, measured as completing four or more antenatal care visits. For the 132 
above-described analyses A-C we applied a simple linear regression model: 133 
(A) Υ =  𝛽 + 𝛽 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛  +  𝜖  134 
(B) Υ =  𝛽 +  𝛽 𝑝𝑜𝑠𝑡 +  𝜖  135 
(C) Υ =  𝛽 +  𝛽 𝑝𝑜𝑠𝑡 +  𝜖  136 
 Υ =  𝛽 +  𝛽 𝑝𝑜𝑠𝑡 +  𝜖  137 
where, for person 𝑖 at time 𝑡, Υ represents the outcome, proportion of women adhering to 138 
recommended antenatal care seeking; 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 is an indicator variable that defines 139 
whether a person belongs to the intervention or control group, taking the value 0 for the 140 
control group and 1 for the intervention group; 𝑝𝑜𝑠𝑡 is an indicator variable that defines which 141 
 
 109
time period the measure belongs to, taking the value 0 before and 1 after the intervention. ε 142 
represents the idiosyncratic error of the regression.  143 
In analysis C, the estimation is conducted separately for the intervention group and the control 144 
group, however no statistical comparison takes place. 145 
For analyses D and E, we performed a DiD analysis: 146 
(D) Υ =  𝛽 +  𝛽 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 + 𝛽 𝑝𝑜𝑠𝑡 + 𝛽 𝑝𝑜𝑠𝑡 ∗ 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 +  𝜖  147 
In analysis D, we adjusted for clustering at district level. In analysis E, the standard errors of 148 
the coefficients do not account for clustering at district level. 149 
We applied sample weights and complex survey design methods in all analyses as provided by 150 
the DHS (8). All analyses were conducted in Stata 14 (13) (see additional file 1 for the code of 151 
the statistical analysis). 152 
 153 
Results 154 
Table 1 displays the analysis results and an interpretation of the findings according to analysis 155 
method.  156 
Table 1 Analysis results and interpretation of findings according to analysis method 157 
 158 
Discussion 159 
We apply in this worked example the most commonly used analysis methods and illustrate 160 
how the findings and their interpretation vary accordingly. For example, a statistical 161 
comparison of the pre-and post-intervention rates of the intervention group only shows a 162 
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clear, statistically significant increase in recommended antenatal care seeking (i.e. analysis B). 163 
A simple observation of before-after differences within the intervention and control groups 164 
(i.e. analysis C) suggests a much larger increase in recommended antenatal care seeking in the 165 
intervention group compared to a much smaller and statistically non-significant improvement 166 
in the control group. However it is unclear how relevant this difference is, given that we have 167 
no direct statistical comparison. The findings of the DiD analysis (i.e. analysis D), however, 168 
imply a relative, yet statistically non-significant, 9% improvement of recommended antenatal 169 
care seeking in the intervention group compared to the control group. In this worked example 170 
we see that the choice of different statistical analysis approaches can lead to very different 171 
interpretations in terms of effect size and statistical precision and thus in terms of drawing 172 
conclusions about intervention effectiveness.  173 
Limitations 174 
Little methodological guidance exists for the correct implementation and analysis of the CBA 175 
study design, despite its importance for public health and health services research and its 176 
increased application in primary research as well as inclusion in systematic reviews (2). In this 177 
paper, we provide only a simple comparison of the most commonly used analysis methods 178 
identified in a previous study. We recommend that detailed guidance be developed, also 179 
including a detailed discussion of different more advanced statistical analysis methods (14).  180 
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